<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Abbott Laboratories</title>
	<atom:link href="http://www.stockbloghub.com/tag/abbott-laboratories/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 16 May 2012 17:53:30 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(STJ) St. Jude Medical Build on Alliance with Abbott Laboratories</title>
		<link>http://www.stockbloghub.com/2012/04/28/stj-st-jude-medical-build-on-alliance-with-abbott-laboratories/99648</link>
		<comments>http://www.stockbloghub.com/2012/04/28/stj-st-jude-medical-build-on-alliance-with-abbott-laboratories/99648#comments</comments>
		<pubDate>Sat, 28 Apr 2012 20:03:09 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[FFR]]></category>
		<category><![CDATA[First Trust FTSE EPRA-NAREIT Glb Real Es]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=99648</guid>
		<description><![CDATA[St. Jude Medical Inc. (STJ) recently disclosed its decision to build on its mutual agreement with Abbott Laboratories (ABT) by revealing the long-term Choice Alliance joint venture. This initiative provides St. Jude Medical the opportunity to incorporate Abbott&#8217;s drug-eluting stents with its cardiovascular, cardiac rhythm management and electrophysiology offerings. Both companies have agreed to endorse each other’s products to their respective customers. Further, Abbott has received the rights to promote St. Jude’s RadiAnalyze Xpress Measurement System and the ILUMIEN PCI Optimization System. This alliance is expected to benefit patient outcomes, as doctors will be able to combine Abbott’s XIENCE family of stents with St. Jude’s optical coherence tomography (OCT) and fractional flow reserve (FFR) know-how to widen the scope of clinical treatments. Abbott Laboratories is a global manufacturer of a ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/04/28/stj-st-jude-medical-build-on-alliance-with-abbott-laboratories/99648/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(C) The Thick of Q1 Earnings Season &#8211; Earnings Preview</title>
		<link>http://www.stockbloghub.com/2012/04/16/c-the-thick-of-q1-earnings-season-earnings-preview/98620</link>
		<comments>http://www.stockbloghub.com/2012/04/16/c-the-thick-of-q1-earnings-season-earnings-preview/98620#comments</comments>
		<pubDate>Mon, 16 Apr 2012 18:14:29 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Financial]]></category>
		<category><![CDATA[Money Center Banks]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[American Express Company]]></category>
		<category><![CDATA[AXP]]></category>
		<category><![CDATA[BAC]]></category>
		<category><![CDATA[Bank of America Corporation]]></category>
		<category><![CDATA[C]]></category>
		<category><![CDATA[Citigroup Inc.]]></category>
		<category><![CDATA[DD]]></category>
		<category><![CDATA[EBAY]]></category>
		<category><![CDATA[eBay Inc.]]></category>
		<category><![CDATA[EI DuPont de Nemours & Company]]></category>
		<category><![CDATA[GE]]></category>
		<category><![CDATA[General Electric Company]]></category>
		<category><![CDATA[Goldman Sachs Group]]></category>
		<category><![CDATA[GS]]></category>
		<category><![CDATA[HAL]]></category>
		<category><![CDATA[Halliburton Company]]></category>
		<category><![CDATA[IBM]]></category>
		<category><![CDATA[INTC]]></category>
		<category><![CDATA[Intel Corporation]]></category>
		<category><![CDATA[International Business Machines Corporation]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[KO]]></category>
		<category><![CDATA[MCD]]></category>
		<category><![CDATA[McDonald's Corporation]]></category>
		<category><![CDATA[Microsoft Corporation]]></category>
		<category><![CDATA[Morgan Stanley]]></category>
		<category><![CDATA[MS]]></category>
		<category><![CDATA[MSFT]]></category>
		<category><![CDATA[Schlumberger Limited]]></category>
		<category><![CDATA[SLB]]></category>
		<category><![CDATA[The Coca-Cola Company]]></category>
		<category><![CDATA[Verizon Communications Inc.]]></category>
		<category><![CDATA[VZ]]></category>
		<category><![CDATA[Yahoo! Inc.]]></category>
		<category><![CDATA[YHOO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=98620</guid>
		<description><![CDATA[We are jumping right into the thick of the first quarter reporting cycle this week, with more than 250 companies coming out with results, including 89 companies from the S&#38;P 500. We will have representation from the who’s who of the corporate world, with a number of bellwether players on tap to come out with results. By the end of the week, we will have a good enough number to judge this earnings season. While earnings will remain the primary focus during the week, we have a number of market-moving economic releases on deck as well. We will get a sense of the consumer economy though the monthly Retail Sales numbers, while the Industrial Production report will give us a good read on the manufacturing sector. Regional manufacturing surveys from ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/04/16/c-the-thick-of-q1-earnings-season-earnings-preview/98620/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(JNJ) Healthcare Reform: Bad News for Big Pharma?</title>
		<link>http://www.stockbloghub.com/2012/04/04/jnj-healthcare-reform-bad-news-for-big-pharma/97425</link>
		<comments>http://www.stockbloghub.com/2012/04/04/jnj-healthcare-reform-bad-news-for-big-pharma/97425#comments</comments>
		<pubDate>Wed, 04 Apr 2012 16:56:03 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=97425</guid>
		<description><![CDATA[Healthcare reform could be a minefield for Big Pharma in the long run. The Patient Protection and Affordable Care Act – less fondly known as “Obamacare” – was the big story to close out the month of March, as the Supreme Court officially took the case. In an effort to figure out which way the vote was going to swing, the media analyzed every word, pause and twitch the justices made. Though all of that heavy-duty analysis doesn’t actually prove anything; while the Court has likely already decided the healthcare mandate’s fate one way or the other, “We the People” probably won’t find out until June. Considering the political left’s repeated complaints about Solicitor General Donald Verrilli Jr. and Deputy Attorney General Edwin S. Kneedler’s admittedly painful performance in explaining ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/04/04/jnj-healthcare-reform-bad-news-for-big-pharma/97425/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYGN) Myriad Inks Deal with Cephalon</title>
		<link>http://www.stockbloghub.com/2012/04/04/mygn-myriad-inks-deal-with-cephalon/97439</link>
		<comments>http://www.stockbloghub.com/2012/04/04/mygn-myriad-inks-deal-with-cephalon/97439#comments</comments>
		<pubDate>Wed, 04 Apr 2012 16:53:51 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Biomarin Pharmaceutical Inc]]></category>
		<category><![CDATA[BMRN]]></category>
		<category><![CDATA[MYGN]]></category>
		<category><![CDATA[Myriad Genetics Inc.]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=97439</guid>
		<description><![CDATA[The recent agreement with Cephalon is another attempt by Myriad Genetics (MYGN) to establish itself as a strong player in the companion diagnostic market. Cephalon is a subsidiary of Teva Pharmaceuticals (TEVA).  Under the agreement, Myriad will conduct BRCA1 and BRCA2 mutation testing on patients with Bracanalysis before being enrolled in a phase I/II clinical study. Over the recent past, the company has entered into similar agreements with players such as Abbott (ABT), Astra Zeneca (AZN) and BioMarin Pharmaceuticals (BMRN) to provide companion diagnostic tests for clinical trial enrollment. Bracanalysis is Myriad’s flagship product, which analyzes the BRCA1 and BRCA2 genes to assess a woman&#8217;s risk for hereditary breast and ovarian cancer. Moreover, the acquisition of RBM (Rules-Based Medicine), made in 2011 would better place Myriad in this arena on ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/04/04/mygn-myriad-inks-deal-with-cephalon/97439/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AAPL) Jan 25: All Eyes on the Fed &#8211; Economic Highlights</title>
		<link>http://www.stockbloghub.com/2012/01/25/aapl-jan-25-all-eyes-on-the-fed-economic-highlights/90815</link>
		<comments>http://www.stockbloghub.com/2012/01/25/aapl-jan-25-all-eyes-on-the-fed-economic-highlights/90815#comments</comments>
		<pubDate>Wed, 25 Jan 2012 18:00:05 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Personal Computers]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[AAPL]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[ADP]]></category>
		<category><![CDATA[Apple Inc.]]></category>
		<category><![CDATA[Automatic Data Processing Inc]]></category>
		<category><![CDATA[BA]]></category>
		<category><![CDATA[Boeing Company]]></category>
		<category><![CDATA[DOV]]></category>
		<category><![CDATA[Dover Corporation]]></category>
		<category><![CDATA[United Technologies Corporation]]></category>
		<category><![CDATA[UTX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=90815</guid>
		<description><![CDATA[The focus today will be on the Fed, as the central bank unveils a new measure as part of its ongoing efforts to improve communication with the markets. The prospect of an even longer timeframe for lower interest rates, as many in the markets are hoping to come out of today’s Fed releases, has the potential to put stocks out of the slumber of the last two trading sessions. A mixed earnings season thus far and the reemergence of Greece worries have prompted stocks to take a pause lately. It will be interesting to see if Apple’s (AAPL) blockbuster results after the close yesterday will have any resonance beyond its own stock price. In this morning’s key earnings releases, Boeing (BA) came out ahead of expectations on both the bottom- ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/01/25/aapl-jan-25-all-eyes-on-the-fed-economic-highlights/90815/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AAPL) Focus Moves Toward the Federal Reserve</title>
		<link>http://www.stockbloghub.com/2012/01/25/aapl-focus-moves-toward-the-federal-reserve/90820</link>
		<comments>http://www.stockbloghub.com/2012/01/25/aapl-focus-moves-toward-the-federal-reserve/90820#comments</comments>
		<pubDate>Wed, 25 Jan 2012 17:59:26 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Personal Computers]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[AAPL]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[ADP]]></category>
		<category><![CDATA[Apple Inc.]]></category>
		<category><![CDATA[Automatic Data Processing Inc]]></category>
		<category><![CDATA[BA]]></category>
		<category><![CDATA[Boeing Company]]></category>
		<category><![CDATA[DOV]]></category>
		<category><![CDATA[Dover Corporation]]></category>
		<category><![CDATA[economy]]></category>
		<category><![CDATA[markets]]></category>
		<category><![CDATA[United Technologies Corporation]]></category>
		<category><![CDATA[UTX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=90820</guid>
		<description><![CDATA[The focus today will be on the Fed, as the Central Bank unveils a new measure as part of its ongoing efforts to improve communication with the markets. The prospect of an even longer timeframe for lower interest rates, as many in the markets are hoping to come out of today’s Fed releases, has the potential to pull stocks out of the slumber of the last two trading sessions. A mixed earnings season thus far and the reemergence of Greece worries have prompted stocks to take a pause lately. It will be interesting to see if Apple’s (AAPL) blockbuster results after the close yesterday will have any resonance beyond its own stock price. In this morning’s key earnings releases, Boeing (BA) came out ahead of expectations on both the bottom- ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/01/25/aapl-focus-moves-toward-the-federal-reserve/90820/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABT) Earnings Season in Full Swing &#8211; Earnings Preview</title>
		<link>http://www.stockbloghub.com/2012/01/24/abt-earnings-season-in-full-swing-earnings-preview/90668</link>
		<comments>http://www.stockbloghub.com/2012/01/24/abt-earnings-season-in-full-swing-earnings-preview/90668#comments</comments>
		<pubDate>Tue, 24 Jan 2012 17:21:15 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AAPL]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[ADP]]></category>
		<category><![CDATA[Apple Inc.]]></category>
		<category><![CDATA[AT&T Inc.]]></category>
		<category><![CDATA[Automatic Data Processing Inc]]></category>
		<category><![CDATA[BA]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Boeing Company]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CAT]]></category>
		<category><![CDATA[Caterpillar Inc.]]></category>
		<category><![CDATA[Chevron Corporation]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[Colgate-Palmolive Company]]></category>
		<category><![CDATA[ConocoPhillips]]></category>
		<category><![CDATA[COP]]></category>
		<category><![CDATA[CSX]]></category>
		<category><![CDATA[CSX Corporation]]></category>
		<category><![CDATA[CVX]]></category>
		<category><![CDATA[DD]]></category>
		<category><![CDATA[DeVry Inc.]]></category>
		<category><![CDATA[DV]]></category>
		<category><![CDATA[EI DuPont de Nemours & Company]]></category>
		<category><![CDATA[GWW]]></category>
		<category><![CDATA[JNPR]]></category>
		<category><![CDATA[Juniper Networks Inc.]]></category>
		<category><![CDATA[T]]></category>
		<category><![CDATA[W.W. Grainger Inc]]></category>
		<category><![CDATA[WDC]]></category>
		<category><![CDATA[Western Digital Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=90668</guid>
		<description><![CDATA[Earnings Preview 1/20/12 Earnings season will be in full swing this week. 422 firms are scheduled to report, and 117 of those will be members of the S&#38;P 500. By the end of the week we should have a very good handle on just how weak or strong this earnings season will be. The firms reporting next week read like a who’s who of American industry.  They.include: Abbott Labs (ABT), Apple (AAPL), Automatic Data Processing (ADP), AT&#38;T (T), Boeing  (BA), Bristol Myers (BMY), Caterpillar (CAT), CSX (CSX), Chevron (CVX), Colgate Palmolive (CL), Conoco Phillips (COP &#8211; Analyst Report) and DuPont (DD) – and that is just in the first four letters of the alphabet! It will also be a moderate week for economic data.  Things will be slow early in ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/01/24/abt-earnings-season-in-full-swing-earnings-preview/90668/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BIIB) Biogen Analyst Neutral on Shares</title>
		<link>http://www.stockbloghub.com/2012/01/21/biib-biogen-analyst-neutral-on-shares/90609</link>
		<comments>http://www.stockbloghub.com/2012/01/21/biib-biogen-analyst-neutral-on-shares/90609#comments</comments>
		<pubDate>Sat, 21 Jan 2012 20:38:57 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Morgan Stanley]]></category>
		<category><![CDATA[MS]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PIMCO Municipal Income Fund II]]></category>
		<category><![CDATA[PML]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=90609</guid>
		<description><![CDATA[We recently reiterated our Neutral recommendation on Biogen Idec (BIIB). Biogen is the market leader in therapies for the treatment of multiple sclerosis (MS). We believe the company will continue to retain a leading position in the MS market. Biogen’s largest product, Avonex, posted sales of $2,518.4 million, up 8.4%, in 2010. We expect Avonex to continue contributing significantly to the top-line thanks to price increases, focused marketing effort, expansion into new markets and positive clinical data. Meanwhile, Tysabri, the company’s second MS product, continues to see an increase in patients despite carrying a “black box” warning for the risk of progressive multifocal leukoencephalopathy (PML) and other cautionary language. Tysabri posted $1.2 billion in sales in 2010. Tysabri’s launch in new markets like India, Brazil, Argentina, the Middle East and ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/01/21/biib-biogen-analyst-neutral-on-shares/90609/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(QGEN) Qiagen Expands with New Deals</title>
		<link>http://www.stockbloghub.com/2012/01/13/qgen-qiagen-expands-with-new-deals/90111</link>
		<comments>http://www.stockbloghub.com/2012/01/13/qgen-qiagen-expands-with-new-deals/90111#comments</comments>
		<pubDate>Fri, 13 Jan 2012 21:09:44 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Alaska Air Group Inc.]]></category>
		<category><![CDATA[ALK]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Biomarin Pharmaceutical Inc]]></category>
		<category><![CDATA[BMRN]]></category>
		<category><![CDATA[Laboratory Corporation of America Holdings]]></category>
		<category><![CDATA[LH]]></category>
		<category><![CDATA[MYGN]]></category>
		<category><![CDATA[Myriad Genetics Inc.]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[QGEN]]></category>
		<category><![CDATA[Qiagen NV]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=90111</guid>
		<description><![CDATA[In an attempt to expand its companion diagnostic portfolio for several types of new anti-cancer drugs, Qiagen (QGEN) recently entered into two different agreements with US biotech companies, namely Insight Genetics, Inc. and Personal Genome Diagnostics Inc. Through the agreement, the company seeks to obtain worldwide exclusive rights for biomarkers for gene mutation. In collaboration with the Tennessee-based molecular diagnostics company Insight Genetics, Qiagen will provide a genetic test with a biomarker for non-small cell lung cancers (NSCLC) that express the abnormal anaplastic lymphoma kinase (ALK) gene. Meanwhile, under the agreement with Maryland-based Personal Genome Diagnostics, Qiagen’s 89% subsidiary Ipsogen obtained rights to genetic testing for mutations of the IDH1 and IDH2 genes for brain cancers, acute myelogenous leukemia (AML) and other malignancies. With the companion diagnostics market expected to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/01/13/qgen-qiagen-expands-with-new-deals/90111/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ATHN) Grading the Investment U Gurus 2011: Marc Lichtenfeld</title>
		<link>http://www.stockbloghub.com/2012/01/09/athn-grading-the-investment-u-gurus-2011-marc-lichtenfeld-2/89047</link>
		<comments>http://www.stockbloghub.com/2012/01/09/athn-grading-the-investment-u-gurus-2011-marc-lichtenfeld-2/89047#comments</comments>
		<pubDate>Mon, 09 Jan 2012 16:44:49 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Business Services]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[AAPL]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[AINV]]></category>
		<category><![CDATA[Allegheny Technologies Inc]]></category>
		<category><![CDATA[Apollo Investment Corporation]]></category>
		<category><![CDATA[Apple Inc.]]></category>
		<category><![CDATA[Athenahealth Inc]]></category>
		<category><![CDATA[ATHN]]></category>
		<category><![CDATA[ATI]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Capstead Mortgage Corporation]]></category>
		<category><![CDATA[CMO]]></category>
		<category><![CDATA[ESRX]]></category>
		<category><![CDATA[Express Scripts Inc.]]></category>
		<category><![CDATA[FAST]]></category>
		<category><![CDATA[Fastenal Company]]></category>
		<category><![CDATA[Genuine Parts Company]]></category>
		<category><![CDATA[GPC]]></category>
		<category><![CDATA[ISIS]]></category>
		<category><![CDATA[Isis Pharmaceuticals Inc]]></category>
		<category><![CDATA[JOE]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>
		<category><![CDATA[MDP]]></category>
		<category><![CDATA[MedcoHealth Solutions Inc.]]></category>
		<category><![CDATA[Meredith Corporation]]></category>
		<category><![CDATA[MHS]]></category>
		<category><![CDATA[NOC]]></category>
		<category><![CDATA[Northrop Grumman Corporation]]></category>
		<category><![CDATA[Old Republic International Corporation]]></category>
		<category><![CDATA[ORI]]></category>
		<category><![CDATA[The St. Joe Company]]></category>
		<category><![CDATA[VAR]]></category>
		<category><![CDATA[Varian Medical Systems Inc]]></category>
		<category><![CDATA[VF Corporation]]></category>
		<category><![CDATA[VFC]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=89047</guid>
		<description><![CDATA[by Marc Lichtenfeld, Investment U Senior Analyst Tuesday, December 20, 2011: Issue #1668 I’m excited when my kids bring home their report cards. They’re terrific students, work hard and always bring home good grades. However, it’s always a little nerve-wracking to tabulate my own report card based on my market calls at the end of the year. The market isn’t nearly as forgiving as a second grade teacher. But nevertheless, it’s an important exercise to see what I got right and what I got wrong… what I may have been a little “early” on. So here goes: In my January 14 column, I talked about the rising trend of healthcare information technology and said two of my favorite stocks in the space were AthenaHealth (Nasdaq: ATHN) and McKesson (NYSE: MCK). ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/01/09/athn-grading-the-investment-u-gurus-2011-marc-lichtenfeld-2/89047/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(JNJ) Pharma &amp; Biotech Stock Review &amp; Outlook &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2011/12/29/jnj-pharma-biotech-stock-review-outlook-industry-outlook/89365</link>
		<comments>http://www.stockbloghub.com/2011/12/29/jnj-pharma-biotech-stock-review-outlook-industry-outlook/89365#comments</comments>
		<pubDate>Thu, 29 Dec 2011 15:55:25 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Alkermes Inc.]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[DENTSPLY International Inc]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[HGSI]]></category>
		<category><![CDATA[Human Genome Sciences Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Perrigo Company]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PRGO]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>
		<category><![CDATA[XRAY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=89365</guid>
		<description><![CDATA[With 2011 coming to an end, the pharmaceutical industry continues to face challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition, pipeline failures and limited late-stage catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. All these factors will lead to a slowdown in global pharmaceutical market growth in the next five years, with major revenue-generating drugs like Lipitor, Plavix, Lexapro and Zyprexa losing exclusivity. In fact, by the end of 2011, drugs worth more than a total of $30 billion will lose patent protection. This includes drugs like Lipitor, Zyprexa and Levaquin. The effect of the genericization of these products will be felt mostly in 2012, which will be a challenging year for several companies. At the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/29/jnj-pharma-biotech-stock-review-outlook-industry-outlook/89365/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(TEVA) Teva Pharmaceutical Industries Provides In-Line 2012 Outlook</title>
		<link>http://www.stockbloghub.com/2011/12/27/teva-teva-pharmaceutical-industries-provides-in-line-2012-outlook/89233</link>
		<comments>http://www.stockbloghub.com/2011/12/27/teva-teva-pharmaceutical-industries-provides-in-line-2012-outlook/89233#comments</comments>
		<pubDate>Wed, 28 Dec 2011 03:58:13 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[PG]]></category>
		<category><![CDATA[Procter & Gamble Company]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=89233</guid>
		<description><![CDATA[Teva Pharmaceutical Industries Ltd. (TEVA) recently provided guidance for 2012. The company expects to earn $5.48 and $5.68 per share on total net sales of about $22 billion. Guidance was generally in line with expectations. While the Zacks Consensus Earnings Estimate, prior to the release of guidance, was $5.62, the Zacks Consensus Revenue Estimate was about $21.8 billion. The Cephalon acquisition is expected to boost 2012 earnings by 20-25 cents. Teva expects to generate $11 billion sales in the US with the EU and Rest of the World (RoW) generating sales of $6.6 billion and $4.4 billion, respectively. The major chunk of revenues ($11.8 billion) will be provided by the generics business. US Generics Biz to Rebound Teva’s US generics business, which has been performing below expectations over the past ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/27/teva-teva-pharmaceutical-industries-provides-in-line-2012-outlook/89233/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ATHN) Grading the Investment U Gurus 2011: Marc Lichtenfeld</title>
		<link>http://www.stockbloghub.com/2011/12/21/athn-grading-the-investment-u-gurus-2011-marc-lichtenfeld/88979</link>
		<comments>http://www.stockbloghub.com/2011/12/21/athn-grading-the-investment-u-gurus-2011-marc-lichtenfeld/88979#comments</comments>
		<pubDate>Wed, 21 Dec 2011 17:42:14 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Business Services]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[AAPL]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[AINV]]></category>
		<category><![CDATA[Allegheny Technologies Inc]]></category>
		<category><![CDATA[Apollo Investment Corporation]]></category>
		<category><![CDATA[Apple Inc.]]></category>
		<category><![CDATA[Athenahealth Inc]]></category>
		<category><![CDATA[ATHN]]></category>
		<category><![CDATA[ATI]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Capstead Mortgage Corporation]]></category>
		<category><![CDATA[CMO]]></category>
		<category><![CDATA[ESRX]]></category>
		<category><![CDATA[Express Scripts Inc.]]></category>
		<category><![CDATA[FAST]]></category>
		<category><![CDATA[Fastenal Company]]></category>
		<category><![CDATA[Genuine Parts Company]]></category>
		<category><![CDATA[GPC]]></category>
		<category><![CDATA[ISIS]]></category>
		<category><![CDATA[Isis Pharmaceuticals Inc]]></category>
		<category><![CDATA[JOE]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>
		<category><![CDATA[MDP]]></category>
		<category><![CDATA[MedcoHealth Solutions Inc.]]></category>
		<category><![CDATA[Meredith Corporation]]></category>
		<category><![CDATA[MHS]]></category>
		<category><![CDATA[NOC]]></category>
		<category><![CDATA[Northrop Grumman Corporation]]></category>
		<category><![CDATA[Old Republic International Corporation]]></category>
		<category><![CDATA[ORI]]></category>
		<category><![CDATA[The St. Joe Company]]></category>
		<category><![CDATA[VAR]]></category>
		<category><![CDATA[Varian Medical Systems Inc]]></category>
		<category><![CDATA[VF Corporation]]></category>
		<category><![CDATA[VFC]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=88979</guid>
		<description><![CDATA[by Marc Lichtenfeld, Investment U Senior Analyst Tuesday, December 20, 2011: Issue #1668 I’m excited when my kids bring home their report cards. They’re terrific students, work hard and always bring home good grades. However, it’s always a little nerve-wracking to tabulate my own report card based on my market calls at the end of the year. The market isn’t nearly as forgiving as a second grade teacher. But nevertheless, it’s an important exercise to see what I got right and what I got wrong… what I may have been a little “early” on. So here goes: In my January 14 column, I talked about the rising trend of healthcare information technology and said two of my favorite stocks in the space were AthenaHealth (Nasdaq: ATHN) and McKesson (NYSE: MCK). ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/21/athn-grading-the-investment-u-gurus-2011-marc-lichtenfeld/88979/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(EU) Emerging Markets: The Way Forward</title>
		<link>http://www.stockbloghub.com/2011/12/07/eu-emerging-markets-the-way-forward/88206</link>
		<comments>http://www.stockbloghub.com/2011/12/07/eu-emerging-markets-the-way-forward/88206#comments</comments>
		<pubDate>Wed, 07 Dec 2011 21:57:17 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Exchange Traded Fund]]></category>
		<category><![CDATA[Financial]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=88206</guid>
		<description><![CDATA[According to Irish orator, philosopher, &#38; politician Edmund Burke, change is the most powerful law of nature. The winds of change seem to be sweeping across the pharmaceutical industry as well. Until recently, most commercialization efforts were focused on the U.S. &#8212; the largest pharmaceutical market &#8212; along with Europe and Japan. However, with factors like pricing pressure in the European Union (EU) and intensifying generic competition affecting sales in large pharmaceutical markets, many leading players in the pharmaceutical space such as Pfizer (PFE), Bristol &#8211; Myers Squibb Company (BMY), Merck (MRK), Eli Lilly (LLY), GlaxoSmithKline (GSK), Astra Zeneca (AZN) and Sanofi-Aventis (SNY), have shifted their focus on emerging (&#8220;pharmerging&#8221;) markets. The key emerging markets targeted by big players in the pharmaceutical space (aka “Big Pharma&#8221;) include China, Russia, Brazil, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/07/eu-emerging-markets-the-way-forward/88206/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYL) Mylan Earns FDA Approval</title>
		<link>http://www.stockbloghub.com/2011/12/05/myl-mylan-earns-fda-approval/88071</link>
		<comments>http://www.stockbloghub.com/2011/12/05/myl-mylan-earns-fda-approval/88071#comments</comments>
		<pubDate>Tue, 06 Dec 2011 00:54:54 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Warner Chilcott Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WCRX]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=88071</guid>
		<description><![CDATA[Generic maker, Mylan Inc. (MYL) recently announced that its Indian subsidiary Mylan Laboratories has received tentative approval from the US Food &#38; Drug Administration (FDA) for a fixed-dose combination of generic versions of Bristol Myers Squibb’s (BMY) drug Reyataz and Abbott Labs&#8216; (ABT) Norvir for the treatment of HIV/AIDS. The fixed drug combination has been pre-qualified to be used in treatment of experienced patients by the World Health Organization (WHO). It can also be used in combination with other antiretroviral (ARV) agents and will be eligible for purchase in certain developing countries. The drug was approved through the President&#8217;s Emergency Plan for AIDS Relief (PEPFAR). The drug will boost Mylan’s already strong portfolio of ARV’s in India. In a separate development, Mylan announced that Warner Chilcott Company (WCRX) filed a ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/05/myl-mylan-earns-fda-approval/88071/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDT) Medical Technology Industry Stock Outlook &#8211; November 2011 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2011/11/18/mdt-medical-technology-industry-stock-outlook-november-2011-industry-outlook/87069</link>
		<comments>http://www.stockbloghub.com/2011/11/18/mdt-medical-technology-industry-stock-outlook-november-2011-industry-outlook/87069#comments</comments>
		<pubDate>Fri, 18 Nov 2011 18:52:43 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[Abiomed Inc]]></category>
		<category><![CDATA[ABMD]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton Dickinson Company]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[CNMD]]></category>
		<category><![CDATA[Conmed Corporation]]></category>
		<category><![CDATA[Edwards Lifesciences Corporation]]></category>
		<category><![CDATA[EW]]></category>
		<category><![CDATA[Flaherty & Crumrine Preferred Income Opportunity F]]></category>
		<category><![CDATA[Intuitive Surgical Inc]]></category>
		<category><![CDATA[ISRG]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[PFO]]></category>
		<category><![CDATA[SMA]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>
		<category><![CDATA[Stryker Corporation]]></category>
		<category><![CDATA[SYK]]></category>
		<category><![CDATA[Symmetry Medical Inc]]></category>
		<category><![CDATA[Thermo Fisher Scientific Inc]]></category>
		<category><![CDATA[THOR]]></category>
		<category><![CDATA[Thoratec Corporation]]></category>
		<category><![CDATA[TMO]]></category>
		<category><![CDATA[VAR]]></category>
		<category><![CDATA[Varian Medical Systems Inc]]></category>
		<category><![CDATA[VOLC]]></category>
		<category><![CDATA[Volcano Corporation]]></category>
		<category><![CDATA[WMGI]]></category>
		<category><![CDATA[Wright Medical Group Inc]]></category>
		<category><![CDATA[Zimmer Holdings Inc]]></category>
		<category><![CDATA[ZMH]]></category>
		<category><![CDATA[ZOLL]]></category>
		<category><![CDATA[Zoll Medical Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=87069</guid>
		<description><![CDATA[The performance of incumbent players in the MedTech industry continued to be hamstrung by a spate of macro issues (including sustained price and procedure volume pressures) in the September quarter. The prevailing macroeconomic factors, pricing headwinds, austerity measures, reimbursement pressure and the impact of health care reform continues to weigh on the medical devices industry, exacerbated by Europe&#8217;s sovereign debt plight. The beleaguered U.S. implantable defibrillator market continues to bother cardiac devices makers, as reflected by sustained implant volume pressure. On the other hand, companies in the orthopedic domain remain affected by a still choppy reconstructive implant market as they faced sustained pressure across hip, knee and spine businesses in the third quarter (albeit to a lesser extent vis-à-vis the sequentially prior quarter). Although a number of these issues are ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/11/18/mdt-medical-technology-industry-stock-outlook-november-2011-industry-outlook/87069/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MS) Oct 19: The Earnings Parade Continues &#8211; Economic Highlights</title>
		<link>http://www.stockbloghub.com/2011/10/20/ms-oct-19-the-earnings-parade-continues-economic-highlights/85423</link>
		<comments>http://www.stockbloghub.com/2011/10/20/ms-oct-19-the-earnings-parade-continues-economic-highlights/85423#comments</comments>
		<pubDate>Thu, 20 Oct 2011 14:44:46 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diversified Investments]]></category>
		<category><![CDATA[Financial]]></category>
		<category><![CDATA[AAPL]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[American Express Company]]></category>
		<category><![CDATA[Apple Inc.]]></category>
		<category><![CDATA[AXP]]></category>
		<category><![CDATA[ConocoPhillips]]></category>
		<category><![CDATA[COP]]></category>
		<category><![CDATA[CSX]]></category>
		<category><![CDATA[CSX Corporation]]></category>
		<category><![CDATA[DaVita Inc.]]></category>
		<category><![CDATA[DVA]]></category>
		<category><![CDATA[EBAY]]></category>
		<category><![CDATA[eBay Inc.]]></category>
		<category><![CDATA[INTC]]></category>
		<category><![CDATA[Intel Corporation]]></category>
		<category><![CDATA[Marathon Oil Corporation]]></category>
		<category><![CDATA[MHP]]></category>
		<category><![CDATA[Morgan Stanley]]></category>
		<category><![CDATA[MRO]]></category>
		<category><![CDATA[MS]]></category>
		<category><![CDATA[Sara Lee Corporation]]></category>
		<category><![CDATA[SLE]]></category>
		<category><![CDATA[The McGraw-Hill Companies Inc]]></category>
		<category><![CDATA[United Technologies Corporation]]></category>
		<category><![CDATA[UTX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=85423</guid>
		<description><![CDATA[The earnings parade continues even as the market tries to come to terms with the Apple surprise and waits for the expected weekend deal out of Europe. We also have economic data this morning about September CPI and Housing Starts, but they will likely have less traction in today&#8217;s market given the focus on earnings and Europe. The September CPI number was largely inline expectations, both on the &#8216;headline&#8217; as well as &#8216;core&#8217; basis. Given the recent pullback in commodity prices and the continued slack in the broader economy, inflation will likely have less staying power than would otherwise be the case. However, persistent &#8216;hot&#8217; CPI readings will make it difficult for Bernanke to rally all FOMC members behind him as we have seen in recent meetings. The Fed dissenters ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/10/20/ms-oct-19-the-earnings-parade-continues-economic-highlights/85423/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MS) Ahead of Wall Street &#8211; October 19, 2011 &#8211; Ahead of Wall Street</title>
		<link>http://www.stockbloghub.com/2011/10/20/ms-ahead-of-wall-street-october-19-2011-ahead-of-wall-street/85469</link>
		<comments>http://www.stockbloghub.com/2011/10/20/ms-ahead-of-wall-street-october-19-2011-ahead-of-wall-street/85469#comments</comments>
		<pubDate>Thu, 20 Oct 2011 14:44:31 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diversified Investments]]></category>
		<category><![CDATA[Financial]]></category>
		<category><![CDATA[AAPL]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[American Express Company]]></category>
		<category><![CDATA[Apple Inc.]]></category>
		<category><![CDATA[AXP]]></category>
		<category><![CDATA[ConocoPhillips]]></category>
		<category><![CDATA[COP]]></category>
		<category><![CDATA[CSX]]></category>
		<category><![CDATA[CSX Corporation]]></category>
		<category><![CDATA[DaVita Inc.]]></category>
		<category><![CDATA[DVA]]></category>
		<category><![CDATA[EBAY]]></category>
		<category><![CDATA[eBay Inc.]]></category>
		<category><![CDATA[INTC]]></category>
		<category><![CDATA[Intel Corporation]]></category>
		<category><![CDATA[Marathon Oil Corporation]]></category>
		<category><![CDATA[MHP]]></category>
		<category><![CDATA[Morgan Stanley]]></category>
		<category><![CDATA[MRO]]></category>
		<category><![CDATA[MS]]></category>
		<category><![CDATA[Sara Lee Corporation]]></category>
		<category><![CDATA[SLE]]></category>
		<category><![CDATA[The McGraw-Hill Companies Inc]]></category>
		<category><![CDATA[United Technologies Corporation]]></category>
		<category><![CDATA[UTX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=85469</guid>
		<description><![CDATA[Wednesday, October 19, 2011 The earnings parade continues even as the market tries to come to terms with the Apple surprise and waits for the expected weekend deal out of Europe. We also have economic data this morning about September CPI and Housing Starts, but they will likely have less traction in today&#8217;s market given the focus on earnings and Europe. The September CPI number was largely inline expectations, both on the &#8216;headline&#8217; as well as &#8216;core&#8217; basis. Given the recent pullback in commodity prices and the continued slack in the broader economy, inflation will likely have less staying power than would otherwise be the case. However, persistent &#8216;hot&#8217; CPI readings will make it difficult for Bernanke to rally all FOMC members behind him as we have seen in recent ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/10/20/ms-ahead-of-wall-street-october-19-2011-ahead-of-wall-street/85469/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AAPL) A Busy Week Ahead &#8211; Earnings Preview</title>
		<link>http://www.stockbloghub.com/2011/10/17/aapl-a-busy-week-ahead-earnings-preview/85152</link>
		<comments>http://www.stockbloghub.com/2011/10/17/aapl-a-busy-week-ahead-earnings-preview/85152#comments</comments>
		<pubDate>Mon, 17 Oct 2011 15:31:27 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Personal Computers]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[8x8 Inc]]></category>
		<category><![CDATA[AAPL]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Acacia Research Corporation]]></category>
		<category><![CDATA[Access National Corporation]]></category>
		<category><![CDATA[Acme Packet Inc]]></category>
		<category><![CDATA[ACTG]]></category>
		<category><![CDATA[ADS]]></category>
		<category><![CDATA[AF]]></category>
		<category><![CDATA[Air Products & Chemicals Inc.]]></category>
		<category><![CDATA[Alaska Air Group Inc.]]></category>
		<category><![CDATA[Alexion Pharmaceuticals Inc]]></category>
		<category><![CDATA[ALK]]></category>
		<category><![CDATA[Alliance Data Systems Corporation]]></category>
		<category><![CDATA[Alliance Financial Corporation]]></category>
		<category><![CDATA[ALNC]]></category>
		<category><![CDATA[Altera Corporation]]></category>
		<category><![CDATA[ALTR]]></category>
		<category><![CDATA[ALXN]]></category>
		<category><![CDATA[American Express Company]]></category>
		<category><![CDATA[American River Bankshares]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amphenol Corporation]]></category>
		<category><![CDATA[AMR]]></category>
		<category><![CDATA[AMR Corporation]]></category>
		<category><![CDATA[AMRB]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[AN]]></category>
		<category><![CDATA[ANCX]]></category>
		<category><![CDATA[AO Smith Corporation]]></category>
		<category><![CDATA[AOS]]></category>
		<category><![CDATA[APD]]></category>
		<category><![CDATA[APH]]></category>
		<category><![CDATA[APKT]]></category>
		<category><![CDATA[APOL]]></category>
		<category><![CDATA[Apollo Group Inc.]]></category>
		<category><![CDATA[Apple Inc.]]></category>
		<category><![CDATA[ASBC]]></category>
		<category><![CDATA[ASR]]></category>
		<category><![CDATA[Associated Banc-Corp]]></category>
		<category><![CDATA[Astoria Financial Corporation]]></category>
		<category><![CDATA[AT&T Inc.]]></category>
		<category><![CDATA[Athenahealth Inc]]></category>
		<category><![CDATA[ATHN]]></category>
		<category><![CDATA[ATMI]]></category>
		<category><![CDATA[ATMI Inc.]]></category>
		<category><![CDATA[AutoNation Inc.]]></category>
		<category><![CDATA[AXP]]></category>
		<category><![CDATA[BAC]]></category>
		<category><![CDATA[Badger Meter Inc]]></category>
		<category><![CDATA[Bank of America Corporation]]></category>
		<category><![CDATA[Banner Corporation]]></category>
		<category><![CDATA[BANR]]></category>
		<category><![CDATA[BAS]]></category>
		<category><![CDATA[Basic Energy Services Inc.]]></category>
		<category><![CDATA[BAX]]></category>
		<category><![CDATA[Baxter International Inc]]></category>
		<category><![CDATA[BB & T Corporation]]></category>
		<category><![CDATA[BBND]]></category>
		<category><![CDATA[BBT]]></category>
		<category><![CDATA[BGG]]></category>
		<category><![CDATA[BigBand Networks Inc]]></category>
		<category><![CDATA[BJ's Restaurants Inc.]]></category>
		<category><![CDATA[BJRI]]></category>
		<category><![CDATA[BK]]></category>
		<category><![CDATA[BlackRock Inc.]]></category>
		<category><![CDATA[BLDR]]></category>
		<category><![CDATA[BLK]]></category>
		<category><![CDATA[BMI]]></category>
		<category><![CDATA[BOOT]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[Bottomline Technologies Inc]]></category>
		<category><![CDATA[BPOP]]></category>
		<category><![CDATA[Briggs & Stratton Corporation]]></category>
		<category><![CDATA[BRKL]]></category>
		<category><![CDATA[BRO]]></category>
		<category><![CDATA[Brookline Bancorp Inc]]></category>
		<category><![CDATA[Brown & Brown Inc.]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[Buffalo Wild Wings Inc.]]></category>
		<category><![CDATA[Builders FirstSource Inc]]></category>
		<category><![CDATA[BWLD]]></category>
		<category><![CDATA[BX]]></category>
		<category><![CDATA[C]]></category>
		<category><![CDATA[CAKE]]></category>
		<category><![CDATA[Capital One Financial Corporation]]></category>
		<category><![CDATA[Cardinal Financial Corporation]]></category>
		<category><![CDATA[Cash America International Inc]]></category>
		<category><![CDATA[Cathay General Bancorp]]></category>
		<category><![CDATA[CATY]]></category>
		<category><![CDATA[CB]]></category>
		<category><![CDATA[CBE]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[CCK]]></category>
		<category><![CDATA[Central Valley Community Bancorp]]></category>
		<category><![CDATA[Cepheid]]></category>
		<category><![CDATA[CFNL]]></category>
		<category><![CDATA[Charles Schwab Corporation]]></category>
		<category><![CDATA[Check Point Software Technologies Limited]]></category>
		<category><![CDATA[Chipotle Mexican Grill Inc.]]></category>
		<category><![CDATA[CHKP]]></category>
		<category><![CDATA[Cirrus Logic Inc.]]></category>
		<category><![CDATA[Citigroup Inc.]]></category>
		<category><![CDATA[City National Corporation]]></category>
		<category><![CDATA[CKH]]></category>
		<category><![CDATA[CLB]]></category>
		<category><![CDATA[CMA]]></category>
		<category><![CDATA[CMG]]></category>
		<category><![CDATA[CNS]]></category>
		<category><![CDATA[CoBiz Financial Inc]]></category>
		<category><![CDATA[COBZ]]></category>
		<category><![CDATA[COF]]></category>
		<category><![CDATA[Cohen & Steers Inc.]]></category>
		<category><![CDATA[COHU]]></category>
		<category><![CDATA[Cohu Inc]]></category>
		<category><![CDATA[Comerica Incorporated]]></category>
		<category><![CDATA[Community Trust Bancorp Inc]]></category>
		<category><![CDATA[Complete Production Services Inc]]></category>
		<category><![CDATA[Compuware Corporation]]></category>
		<category><![CDATA[Cooper Industries Limited]]></category>
		<category><![CDATA[Core Laboratories NV]]></category>
		<category><![CDATA[Covanta Holding Corporation]]></category>
		<category><![CDATA[CPHD]]></category>
		<category><![CDATA[CPWR]]></category>
		<category><![CDATA[CPX]]></category>
		<category><![CDATA[CREE]]></category>
		<category><![CDATA[Cree Inc.]]></category>
		<category><![CDATA[Crown Holdings Inc.]]></category>
		<category><![CDATA[CRUS]]></category>
		<category><![CDATA[CSH]]></category>
		<category><![CDATA[CSX]]></category>
		<category><![CDATA[CSX Corporation]]></category>
		<category><![CDATA[CTBI]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[CVA]]></category>
		<category><![CDATA[CVB Financial Corporation]]></category>
		<category><![CDATA[CVBF]]></category>
		<category><![CDATA[CVCY]]></category>
		<category><![CDATA[CY]]></category>
		<category><![CDATA[Cymer Inc.]]></category>
		<category><![CDATA[CYMI]]></category>
		<category><![CDATA[CYN]]></category>
		<category><![CDATA[Cypress Semiconductor Corporation]]></category>
		<category><![CDATA[CYT]]></category>
		<category><![CDATA[Cytec Industries Inc.]]></category>
		<category><![CDATA[Danaher Corporation]]></category>
		<category><![CDATA[Datalink Corporation]]></category>
		<category><![CDATA[DHR]]></category>
		<category><![CDATA[Diamond Offshore Drilling Inc]]></category>
		<category><![CDATA[Diamondrock Hospitality Company]]></category>
		<category><![CDATA[DO]]></category>
		<category><![CDATA[Dominos Pizza Inc.]]></category>
		<category><![CDATA[DOV]]></category>
		<category><![CDATA[Dover Corporation]]></category>
		<category><![CDATA[DPZ]]></category>
		<category><![CDATA[DRH]]></category>
		<category><![CDATA[DTLK]]></category>
		<category><![CDATA[E*TRADE Financial Corporation]]></category>
		<category><![CDATA[East West Bancorp Inc]]></category>
		<category><![CDATA[EastGroup Properties Inc]]></category>
		<category><![CDATA[EBAY]]></category>
		<category><![CDATA[eBay Inc.]]></category>
		<category><![CDATA[ECA]]></category>
		<category><![CDATA[EDU]]></category>
		<category><![CDATA[Edwards Lifesciences Corporation]]></category>
		<category><![CDATA[EFII]]></category>
		<category><![CDATA[EGHT]]></category>
		<category><![CDATA[EGP]]></category>
		<category><![CDATA[Electronics for Imaging Inc.]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[ELS]]></category>
		<category><![CDATA[EMC]]></category>
		<category><![CDATA[EMC Corporation]]></category>
		<category><![CDATA[Encana Corporation]]></category>
		<category><![CDATA[ENZ]]></category>
		<category><![CDATA[Enzo Biochem Inc]]></category>
		<category><![CDATA[EPAY]]></category>
		<category><![CDATA[Equity Lifestyles Properties Inc]]></category>
		<category><![CDATA[ERIC]]></category>
		<category><![CDATA[ESI]]></category>
		<category><![CDATA[ETFC]]></category>
		<category><![CDATA[EW]]></category>
		<category><![CDATA[EWBC]]></category>
		<category><![CDATA[EXPO]]></category>
		<category><![CDATA[Exponent Inc.]]></category>
		<category><![CDATA[F.N.B. Corporation]]></category>
		<category><![CDATA[FCFS]]></category>
		<category><![CDATA[FCX]]></category>
		<category><![CDATA[FFIN]]></category>
		<category><![CDATA[FHN]]></category>
		<category><![CDATA[Fidelity National Financial Inc]]></category>
		<category><![CDATA[Fifth Third Bancorp]]></category>
		<category><![CDATA[First Cash Financial Services Inc]]></category>
		<category><![CDATA[First Financial Bankshares Inc]]></category>
		<category><![CDATA[First Horizon National Corporation]]></category>
		<category><![CDATA[First Niagara Financial Group Inc]]></category>
		<category><![CDATA[FITB]]></category>
		<category><![CDATA[FLEX]]></category>
		<category><![CDATA[Flexsteel Industries Inc]]></category>
		<category><![CDATA[Flextronics International Limited]]></category>
		<category><![CDATA[FLIR]]></category>
		<category><![CDATA[FLIR Systems Inc]]></category>
		<category><![CDATA[FLXS]]></category>
		<category><![CDATA[FNB]]></category>
		<category><![CDATA[FNF]]></category>
		<category><![CDATA[FNFG]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[Forward Air Corporation]]></category>
		<category><![CDATA[Freeport-McMoRan Copper & Gold Inc]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[FSI International Inc]]></category>
		<category><![CDATA[FSII]]></category>
		<category><![CDATA[FULT]]></category>
		<category><![CDATA[Fulton Financial Corporation]]></category>
		<category><![CDATA[FWRD]]></category>
		<category><![CDATA[Gannett Company Inc]]></category>
		<category><![CDATA[Gardner Denver Inc.]]></category>
		<category><![CDATA[GATX Corporation]]></category>
		<category><![CDATA[GCI]]></category>
		<category><![CDATA[GDI]]></category>
		<category><![CDATA[GE]]></category>
		<category><![CDATA[General Electric Company]]></category>
		<category><![CDATA[Gentex Corporation]]></category>
		<category><![CDATA[Genuine Parts Company]]></category>
		<category><![CDATA[GHL]]></category>
		<category><![CDATA[GLF]]></category>
		<category><![CDATA[GMT]]></category>
		<category><![CDATA[GNTX]]></category>
		<category><![CDATA[Goldman Sachs Group]]></category>
		<category><![CDATA[GPC]]></category>
		<category><![CDATA[Greenhill & Co Inc.]]></category>
		<category><![CDATA[Grupo Aeroportuario Del Sureste SA de CV]]></category>
		<category><![CDATA[GS]]></category>
		<category><![CDATA[Gulfmark Offshore Inc.]]></category>
		<category><![CDATA[GWW]]></category>
		<category><![CDATA[HA]]></category>
		<category><![CDATA[HAFC]]></category>
		<category><![CDATA[HAL]]></category>
		<category><![CDATA[Halliburton Company]]></category>
		<category><![CDATA[Hanesbrands Inc.]]></category>
		<category><![CDATA[Hanmi Financial Corporation]]></category>
		<category><![CDATA[HAR]]></category>
		<category><![CDATA[Harley-Davidson Inc.]]></category>
		<category><![CDATA[Harman International Industries Inc]]></category>
		<category><![CDATA[HAS]]></category>
		<category><![CDATA[Hasbro Inc.]]></category>
		<category><![CDATA[Hawaiian Holdings Inc.]]></category>
		<category><![CDATA[HBAN]]></category>
		<category><![CDATA[HBI]]></category>
		<category><![CDATA[HCBK]]></category>
		<category><![CDATA[HCCI]]></category>
		<category><![CDATA[Heartland Express Inc]]></category>
		<category><![CDATA[Heritage-Crystal Clean Inc]]></category>
		<category><![CDATA[HITT]]></category>
		<category><![CDATA[Hittite Microwave Corporation]]></category>
		<category><![CDATA[HNI]]></category>
		<category><![CDATA[HNI Corporation]]></category>
		<category><![CDATA[HOG]]></category>
		<category><![CDATA[HOMB]]></category>
		<category><![CDATA[Home Bancshares Inc (Conway AR)]]></category>
		<category><![CDATA[HON]]></category>
		<category><![CDATA[Honeywell International Inc.]]></category>
		<category><![CDATA[HTLD]]></category>
		<category><![CDATA[HUBB]]></category>
		<category><![CDATA[Hubbell Inc B Shares]]></category>
		<category><![CDATA[Hudson City Bancorp Inc]]></category>
		<category><![CDATA[Huntington Bancshares Inc]]></category>
		<category><![CDATA[IBKR]]></category>
		<category><![CDATA[IBM]]></category>
		<category><![CDATA[ICLR]]></category>
		<category><![CDATA[ICON plc]]></category>
		<category><![CDATA[ICU Medical Inc]]></category>
		<category><![CDATA[ICUI]]></category>
		<category><![CDATA[IDEX Corporation]]></category>
		<category><![CDATA[IDEXX Laboratories Inc.]]></category>
		<category><![CDATA[IDXX]]></category>
		<category><![CDATA[IEX]]></category>
		<category><![CDATA[IIIN]]></category>
		<category><![CDATA[INDB]]></category>
		<category><![CDATA[Independent Bank Corporation]]></category>
		<category><![CDATA[INFA]]></category>
		<category><![CDATA[Infinera Corporation]]></category>
		<category><![CDATA[INFN]]></category>
		<category><![CDATA[Informatica Corporation]]></category>
		<category><![CDATA[Ingersoll-Rand Company Limited]]></category>
		<category><![CDATA[Insteel Industries Inc.]]></category>
		<category><![CDATA[INTC]]></category>
		<category><![CDATA[Intel Corporation]]></category>
		<category><![CDATA[Interactive Brokers Group Inc]]></category>
		<category><![CDATA[International Business Machines]]></category>
		<category><![CDATA[Intuitive Surgical Inc]]></category>
		<category><![CDATA[IR]]></category>
		<category><![CDATA[ISRG]]></category>
		<category><![CDATA[ITT Educational Services Inc.]]></category>
		<category><![CDATA[Ixia]]></category>
		<category><![CDATA[JAKK]]></category>
		<category><![CDATA[JAKKS Pacific Inc.]]></category>
		<category><![CDATA[Janus Capital Group Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[JNPR]]></category>
		<category><![CDATA[JNS]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Journal Communications Inc.]]></category>
		<category><![CDATA[JRN]]></category>
		<category><![CDATA[Juniper Networks Inc.]]></category>
		<category><![CDATA[Kansas City Southern]]></category>
		<category><![CDATA[Kayne Anderson Energy Development Company]]></category>
		<category><![CDATA[KCI]]></category>
		<category><![CDATA[KED]]></category>
		<category><![CDATA[Kensey Nash Corporation]]></category>
		<category><![CDATA[KEY]]></category>
		<category><![CDATA[KeyCorp]]></category>
		<category><![CDATA[Kinder Morgan Energy Partners LP]]></category>
		<category><![CDATA[Kinder Morgan Management LLC]]></category>
		<category><![CDATA[Kinetic Concepts Inc]]></category>
		<category><![CDATA[KMP]]></category>
		<category><![CDATA[KMR]]></category>
		<category><![CDATA[Knight Transportation Inc]]></category>
		<category><![CDATA[KNL]]></category>
		<category><![CDATA[Knoll Inc.]]></category>
		<category><![CDATA[KNSY]]></category>
		<category><![CDATA[KNX]]></category>
		<category><![CDATA[KO]]></category>
		<category><![CDATA[Koninklijke Philips Electronics NV]]></category>
		<category><![CDATA[KSU]]></category>
		<category><![CDATA[Laboratory Corporation of America Holdings]]></category>
		<category><![CDATA[Lacrosse Footwear Inc.]]></category>
		<category><![CDATA[Lakeland Bancorp Inc]]></category>
		<category><![CDATA[Lam Research Corporation]]></category>
		<category><![CDATA[Lare Holdings Inc]]></category>
		<category><![CDATA[LaSalle Hotel Properties]]></category>
		<category><![CDATA[Lattice Semiconductor Corporation]]></category>
		<category><![CDATA[LBAI]]></category>
		<category><![CDATA[LCC]]></category>
		<category><![CDATA[LH]]></category>
		<category><![CDATA[LHO]]></category>
		<category><![CDATA[Life Time Fitness Inc.]]></category>
		<category><![CDATA[Linear Technology Corporation]]></category>
		<category><![CDATA[LLTC]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Lm Ericsson Telephone Company]]></category>
		<category><![CDATA[LNCR]]></category>
		<category><![CDATA[LRCX]]></category>
		<category><![CDATA[LSCC]]></category>
		<category><![CDATA[LTM]]></category>
		<category><![CDATA[LUFK]]></category>
		<category><![CDATA[Lufkin Industries Inc.]]></category>
		<category><![CDATA[LUV]]></category>
		<category><![CDATA[M&T Bank Corporation]]></category>
		<category><![CDATA[MAN]]></category>
		<category><![CDATA[MANH]]></category>
		<category><![CDATA[Manhattan Associates Inc.]]></category>
		<category><![CDATA[Manpower Inc.]]></category>
		<category><![CDATA[Marten Transport Limited]]></category>
		<category><![CDATA[Mattson Technology Inc]]></category>
		<category><![CDATA[Maxim Integrated Products Inc]]></category>
		<category><![CDATA[Mb Financial Inc]]></category>
		<category><![CDATA[MBFI]]></category>
		<category><![CDATA[MBWM]]></category>
		<category><![CDATA[MCD]]></category>
		<category><![CDATA[McDonald's Corporation]]></category>
		<category><![CDATA[McMoRan Exploration Company]]></category>
		<category><![CDATA[MCRI]]></category>
		<category><![CDATA[Mercantile Bank Corporation]]></category>
		<category><![CDATA[MGIC Investment Corporation]]></category>
		<category><![CDATA[MHP]]></category>
		<category><![CDATA[Microsoft Corporation]]></category>
		<category><![CDATA[MKS Instruments Inc.]]></category>
		<category><![CDATA[MKSI]]></category>
		<category><![CDATA[MMR]]></category>
		<category><![CDATA[MNI]]></category>
		<category><![CDATA[MNRO]]></category>
		<category><![CDATA[Monarch Casino & Resort Inc.]]></category>
		<category><![CDATA[Monro Muffler Brake Inc.]]></category>
		<category><![CDATA[Morgan Stanley]]></category>
		<category><![CDATA[MRTN]]></category>
		<category><![CDATA[MS]]></category>
		<category><![CDATA[MSFT]]></category>
		<category><![CDATA[MTB]]></category>
		<category><![CDATA[MTG]]></category>
		<category><![CDATA[MTSN]]></category>
		<category><![CDATA[MXIM]]></category>
		<category><![CDATA[MYE]]></category>
		<category><![CDATA[Myers Industries Inc.]]></category>
		<category><![CDATA[NBL]]></category>
		<category><![CDATA[NE]]></category>
		<category><![CDATA[NetScout Systems Inc]]></category>
		<category><![CDATA[New Oriental Education & Technology Group]]></category>
		<category><![CDATA[New York Community Bancorp Inc]]></category>
		<category><![CDATA[Newfield Exploration Company]]></category>
		<category><![CDATA[NFX]]></category>
		<category><![CDATA[Noble Corporation]]></category>
		<category><![CDATA[Noble Energy Inc]]></category>
		<category><![CDATA[NOK]]></category>
		<category><![CDATA[Nokia Corporation]]></category>
		<category><![CDATA[Northern Trust Corporation]]></category>
		<category><![CDATA[NTCT]]></category>
		<category><![CDATA[NTRS]]></category>
		<category><![CDATA[Nucor Corporation]]></category>
		<category><![CDATA[NUE]]></category>
		<category><![CDATA[NVE Corporation]]></category>
		<category><![CDATA[NVEC]]></category>
		<category><![CDATA[NVR]]></category>
		<category><![CDATA[NVR Inc.]]></category>
		<category><![CDATA[NYB]]></category>
		<category><![CDATA[NYT]]></category>
		<category><![CDATA[OceanFirst Financial Corporation]]></category>
		<category><![CDATA[OCFC]]></category>
		<category><![CDATA[OKSB]]></category>
		<category><![CDATA[OMC]]></category>
		<category><![CDATA[Omnicom Group Inc.]]></category>
		<category><![CDATA[ORB]]></category>
		<category><![CDATA[Orbital Sciences Corporation]]></category>
		<category><![CDATA[Pacific Continental Corporation]]></category>
		<category><![CDATA[Packaging Corporation of America]]></category>
		<category><![CDATA[Park National Corporation]]></category>
		<category><![CDATA[Parker Hannifin Corporation]]></category>
		<category><![CDATA[Patni Computer Systems Limited]]></category>
		<category><![CDATA[Patriot Coal Corporation]]></category>
		<category><![CDATA[PBCT]]></category>
		<category><![CDATA[PCBK]]></category>
		<category><![CDATA[PCX]]></category>
		<category><![CDATA[PDS]]></category>
		<category><![CDATA[PENN]]></category>
		<category><![CDATA[Penn National Gaming Inc.]]></category>
		<category><![CDATA[Peoples United Financial Inc]]></category>
		<category><![CDATA[PetMed Express Inc.]]></category>
		<category><![CDATA[PETS]]></category>
		<category><![CDATA[PFBC]]></category>
		<category><![CDATA[PGI]]></category>
		<category><![CDATA[PH]]></category>
		<category><![CDATA[PHG]]></category>
		<category><![CDATA[Philip Morris International Inc]]></category>
		<category><![CDATA[PII]]></category>
		<category><![CDATA[Pinnacle Financial Partners Inc]]></category>
		<category><![CDATA[Piper Jaffray Companies]]></category>
		<category><![CDATA[Pixelworks Inc]]></category>
		<category><![CDATA[PJC]]></category>
		<category><![CDATA[PKG]]></category>
		<category><![CDATA[Platinum Underwriters Holdings Limited]]></category>
		<category><![CDATA[PLCM]]></category>
		<category><![CDATA[PM]]></category>
		<category><![CDATA[PNC]]></category>
		<category><![CDATA[PNC Financial Services Group Inc]]></category>
		<category><![CDATA[PNFP]]></category>
		<category><![CDATA[Polaris Industries Inc.]]></category>
		<category><![CDATA[Polycom Inc.]]></category>
		<category><![CDATA[POOL]]></category>
		<category><![CDATA[Pool Corp]]></category>
		<category><![CDATA[Popular Inc]]></category>
		<category><![CDATA[PPG]]></category>
		<category><![CDATA[PPG Industries Inc.]]></category>
		<category><![CDATA[Precision Drilling Trust]]></category>
		<category><![CDATA[Preferred Bank]]></category>
		<category><![CDATA[Premiere Global Services Inc.]]></category>
		<category><![CDATA[PRK]]></category>
		<category><![CDATA[Prosperity Bancshares Inc.]]></category>
		<category><![CDATA[PRSP]]></category>
		<category><![CDATA[PTI]]></category>
		<category><![CDATA[PTP]]></category>
		<category><![CDATA[PXLW]]></category>
		<category><![CDATA[Rambus Inc.]]></category>
		<category><![CDATA[Raymond James Financial Inc.]]></category>
		<category><![CDATA[RCKY]]></category>
		<category><![CDATA[Renaissance Learning Inc.]]></category>
		<category><![CDATA[Renasant Corporation]]></category>
		<category><![CDATA[RHI]]></category>
		<category><![CDATA[Riverbed Technology Inc.]]></category>
		<category><![CDATA[RJF]]></category>
		<category><![CDATA[RLI]]></category>
		<category><![CDATA[RLI Corporation]]></category>
		<category><![CDATA[RLRN]]></category>
		<category><![CDATA[RMBS]]></category>
		<category><![CDATA[RNST]]></category>
		<category><![CDATA[Robert Half International Inc.]]></category>
		<category><![CDATA[ROC]]></category>
		<category><![CDATA[Rockwood Holdings Inc.]]></category>
		<category><![CDATA[Rocky Brands Inc.]]></category>
		<category><![CDATA[RRR]]></category>
		<category><![CDATA[RSC Holdings Inc.]]></category>
		<category><![CDATA[RVBD]]></category>
		<category><![CDATA[Safe Bulkers Inc.]]></category>
		<category><![CDATA[SanDisk Corporation]]></category>
		<category><![CDATA[Sandy Spring Bancorp Inc]]></category>
		<category><![CDATA[SASR]]></category>
		<category><![CDATA[SB]]></category>
		<category><![CDATA[SBCF]]></category>
		<category><![CDATA[Schlumberger Limited]]></category>
		<category><![CDATA[SCHN]]></category>
		<category><![CDATA[Schnitzer Steel Industries Inc]]></category>
		<category><![CDATA[SCHW]]></category>
		<category><![CDATA[SCL]]></category>
		<category><![CDATA[SCSS]]></category>
		<category><![CDATA[Seacoast Banking Corporation of Florida]]></category>
		<category><![CDATA[Seacor Holdings Inc.]]></category>
		<category><![CDATA[Seagate Technology]]></category>
		<category><![CDATA[SEI Investments Company]]></category>
		<category><![CDATA[SEIC]]></category>
		<category><![CDATA[Select Comfort Corporation]]></category>
		<category><![CDATA[Sensient Technologies Corporation]]></category>
		<category><![CDATA[SFNC]]></category>
		<category><![CDATA[Shaw Communications Inc.]]></category>
		<category><![CDATA[Simmons First National Corporation]]></category>
		<category><![CDATA[SIVB]]></category>
		<category><![CDATA[SJR]]></category>
		<category><![CDATA[SLB]]></category>
		<category><![CDATA[SLM]]></category>
		<category><![CDATA[Slm Corporation]]></category>
		<category><![CDATA[SNA]]></category>
		<category><![CDATA[Snap-on Inc.]]></category>
		<category><![CDATA[SNDK]]></category>
		<category><![CDATA[SON]]></category>
		<category><![CDATA[SONC]]></category>
		<category><![CDATA[Sonic Corporation]]></category>
		<category><![CDATA[Sonoco Products Company]]></category>
		<category><![CDATA[Southwest Airlines Company]]></category>
		<category><![CDATA[Southwest Bancorp Inc]]></category>
		<category><![CDATA[Spartan Stores Inc.]]></category>
		<category><![CDATA[SPTN]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[Stanley Black & Decker]]></category>
		<category><![CDATA[Stanley Furniture Company Inc]]></category>
		<category><![CDATA[State Street Corporation]]></category>
		<category><![CDATA[Steel Dynamics Inc.]]></category>
		<category><![CDATA[Stepan Company]]></category>
		<category><![CDATA[STI]]></category>
		<category><![CDATA[STJ]]></category>
		<category><![CDATA[STLD]]></category>
		<category><![CDATA[STLY]]></category>
		<category><![CDATA[Stryker Corporation]]></category>
		<category><![CDATA[STT]]></category>
		<category><![CDATA[STX]]></category>
		<category><![CDATA[SunTrust Banks Inc.]]></category>
		<category><![CDATA[SUPERVALU Inc.]]></category>
		<category><![CDATA[SVB Financial Group]]></category>
		<category><![CDATA[SVU]]></category>
		<category><![CDATA[SWK]]></category>
		<category><![CDATA[SXT]]></category>
		<category><![CDATA[SY Bancorp Inc.]]></category>
		<category><![CDATA[SYBT]]></category>
		<category><![CDATA[SYK]]></category>
		<category><![CDATA[SYNA]]></category>
		<category><![CDATA[Synaptics Inc]]></category>
		<category><![CDATA[T]]></category>
		<category><![CDATA[Taubman Centers Inc.]]></category>
		<category><![CDATA[TBBK]]></category>
		<category><![CDATA[TCB]]></category>
		<category><![CDATA[TCBI]]></category>
		<category><![CDATA[TCF Financial Corporation]]></category>
		<category><![CDATA[TCO]]></category>
		<category><![CDATA[Temple-Inland Inc.]]></category>
		<category><![CDATA[Tempur Pedic International Inc]]></category>
		<category><![CDATA[TESS]]></category>
		<category><![CDATA[TESSCO Technologies Inc.]]></category>
		<category><![CDATA[Texas Capital BancShares Inc.]]></category>
		<category><![CDATA[Textron Inc.]]></category>
		<category><![CDATA[The Bancorp Inc]]></category>
		<category><![CDATA[The Bank of New York Mellon Corporation]]></category>
		<category><![CDATA[The Blackstone Group]]></category>
		<category><![CDATA[The Cheesecake Factory Incorporated]]></category>
		<category><![CDATA[The Chubb Corporation]]></category>
		<category><![CDATA[The Coca-Cola Company]]></category>
		<category><![CDATA[The McClatchy Company]]></category>
		<category><![CDATA[The McGraw-Hill Companies Inc]]></category>
		<category><![CDATA[The New York Times Company]]></category>
		<category><![CDATA[The Travelers Companies Inc.]]></category>
		<category><![CDATA[Thomas & Betts Corporation]]></category>
		<category><![CDATA[TIN]]></category>
		<category><![CDATA[TNB]]></category>
		<category><![CDATA[TPX]]></category>
		<category><![CDATA[Tractor Supply Company]]></category>
		<category><![CDATA[Travelzoo Inc.]]></category>
		<category><![CDATA[TRIB]]></category>
		<category><![CDATA[Trinity Biotech plc]]></category>
		<category><![CDATA[TRV]]></category>
		<category><![CDATA[TSCO]]></category>
		<category><![CDATA[TXT]]></category>
		<category><![CDATA[TZOO]]></category>
		<category><![CDATA[UAL]]></category>
		<category><![CDATA[UBNK]]></category>
		<category><![CDATA[Ultratech Inc.]]></category>
		<category><![CDATA[UMPQ]]></category>
		<category><![CDATA[Umpqua Holdings Corporation]]></category>
		<category><![CDATA[UNF]]></category>
		<category><![CDATA[UNH]]></category>
		<category><![CDATA[UniFirst Corporation]]></category>
		<category><![CDATA[Union Pacific Corporation]]></category>
		<category><![CDATA[United Continental Holdings]]></category>
		<category><![CDATA[United Financial Bancorp]]></category>
		<category><![CDATA[United Rentals Inc]]></category>
		<category><![CDATA[United Technologies Corporation]]></category>
		<category><![CDATA[Unitedhealth Group Inc.]]></category>
		<category><![CDATA[UNP]]></category>
		<category><![CDATA[URI]]></category>
		<category><![CDATA[US Airways Group Inc.]]></category>
		<category><![CDATA[Us Bancorp]]></category>
		<category><![CDATA[USA Truck Inc.]]></category>
		<category><![CDATA[USAK]]></category>
		<category><![CDATA[USB]]></category>
		<category><![CDATA[USG]]></category>
		<category><![CDATA[USG Corporation]]></category>
		<category><![CDATA[UTEK]]></category>
		<category><![CDATA[UTX]]></category>
		<category><![CDATA[Valley National Bancorp]]></category>
		<category><![CDATA[VCBI]]></category>
		<category><![CDATA[Verizon Communications Inc.]]></category>
		<category><![CDATA[Viad Corporation]]></category>
		<category><![CDATA[Virginia Commerce Bancorp Inc]]></category>
		<category><![CDATA[VLY]]></category>
		<category><![CDATA[VMW]]></category>
		<category><![CDATA[VMware Inc.]]></category>
		<category><![CDATA[VVI]]></category>
		<category><![CDATA[VZ]]></category>
		<category><![CDATA[W.W. Grainger Inc]]></category>
		<category><![CDATA[WABC]]></category>
		<category><![CDATA[WAL]]></category>
		<category><![CDATA[Washington Federal Inc]]></category>
		<category><![CDATA[Waste Connections Inc.]]></category>
		<category><![CDATA[Watsco Inc.]]></category>
		<category><![CDATA[WCC]]></category>
		<category><![CDATA[WCN]]></category>
		<category><![CDATA[WD-40 Company]]></category>
		<category><![CDATA[WDC]]></category>
		<category><![CDATA[WDFC]]></category>
		<category><![CDATA[Wells Fargo & Company]]></category>
		<category><![CDATA[WERN]]></category>
		<category><![CDATA[Werner Enterprises Inc.]]></category>
		<category><![CDATA[WESCO International Inc.]]></category>
		<category><![CDATA[Westamerica BanCorporation]]></category>
		<category><![CDATA[Westell Technologies Inc]]></category>
		<category><![CDATA[Western Alliance Bancorporation]]></category>
		<category><![CDATA[Western Digital Corporation]]></category>
		<category><![CDATA[Westwood Holdings Group Inc]]></category>
		<category><![CDATA[WFC]]></category>
		<category><![CDATA[WFSL]]></category>
		<category><![CDATA[WHG]]></category>
		<category><![CDATA[WNS]]></category>
		<category><![CDATA[WNS (Holdings) Limited]]></category>
		<category><![CDATA[WSO]]></category>
		<category><![CDATA[WSTL]]></category>
		<category><![CDATA[WYNN]]></category>
		<category><![CDATA[Wynn Resorts Limited]]></category>
		<category><![CDATA[Xilinx Inc.]]></category>
		<category><![CDATA[XLNX]]></category>
		<category><![CDATA[XXIA]]></category>
		<category><![CDATA[Yahoo! Inc.]]></category>
		<category><![CDATA[YHOO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=85152</guid>
		<description><![CDATA[Earnings Preview 10/14/11 While the earnings season kicked off this past week, only 38 firms reported. The game really gets under way next week, when we will get reports from 336 firms, including 99 members of the S&#38;P 500. Thus, by the end of the week we will have a very good idea of how the overall season will go. Not only will there be a lot of reports, but many of those we get will be very important ones. The table at the end of this report reads like a who’s who of American industry, including: Apple (AAPL), American Express (AXP), Bank of America (BAC), Citigroup (C), General Electric (GE), Goldman Sachs (GS), IBM (IBM), Intel (INTC) and McDonald’s (MCD). And that&#8217;s just the first half of the alphabet! ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/10/17/aapl-a-busy-week-ahead-earnings-preview/85152/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(EU) Pharmaceuticals Stock Outlook &#8211; September 2011 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2011/09/23/eu-pharmaceuticals-stock-outlook-september-2011-industry-outlook/83930</link>
		<comments>http://www.stockbloghub.com/2011/09/23/eu-pharmaceuticals-stock-outlook-september-2011-industry-outlook/83930#comments</comments>
		<pubDate>Fri, 23 Sep 2011 18:59:59 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Exchange Traded Fund]]></category>
		<category><![CDATA[Financial]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[AGN]]></category>
		<category><![CDATA[Allergan Inc.]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Endo Pharmaceuticals Holdings Inc]]></category>
		<category><![CDATA[ENDP]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[ICAgen Inc]]></category>
		<category><![CDATA[ICGN]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[Perrigo Company]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PRGO]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=83930</guid>
		<description><![CDATA[The pharmaceutical industry continues to be impacted by major issues such as sluggish prescription trends, European Union (EU) pricing pressure, intensifying generic competition and limited late-stage catalysts. The next five years are expected to witness a significant imbalance between new product launches and patent expirations. All these factors will lead to a slowdown in global pharmaceutical market growth in the next five years. Major revenue generating drugs like Lipitor, Plavix, Lexapro and Zyprexa are expected to confront generic competition over the next five years. In fact, revenues in excess of $30 billion are expected to be lost in 2011 itself due to key drugs like Lipitor and Zyprexa going off-patent. The impact of the genericization of these drugs will be felt significantly in 2012, which will be a challenging year ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/23/eu-pharmaceuticals-stock-outlook-september-2011-industry-outlook/83930/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BAC) Market Outlook Murky &#8211; Valuations Compelling</title>
		<link>http://www.stockbloghub.com/2011/09/20/bac-market-outlook-murky-valuations-compelling/83545</link>
		<comments>http://www.stockbloghub.com/2011/09/20/bac-market-outlook-murky-valuations-compelling/83545#comments</comments>
		<pubDate>Tue, 20 Sep 2011 19:53:59 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Financial]]></category>
		<category><![CDATA[Money Center Banks]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[AFL]]></category>
		<category><![CDATA[AFLAC Inc.]]></category>
		<category><![CDATA[BAC]]></category>
		<category><![CDATA[Bank of America Corporation]]></category>
		<category><![CDATA[Genuine Parts Company]]></category>
		<category><![CDATA[GPC]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=83545</guid>
		<description><![CDATA[The Earnings Picture Second quarter earnings season is over; the attention now shifts to the third quarter. With the exception of a handful of financials, most notably Bank of America (BAC), which had a $12 billion negative swing in net income from last year, this has been another great earnings season. The year-over-year growth rate for the S&#38;P 500 is 11.9%, way off the 17.1% pace posted in the first quarter. However, it you exclude the financial sector, growth is 19.3%, actually up slightly from the 19.1% pace of the first quarter. At the beginning of earnings season, growth of 9.7% was expected, 12.2% ex-financials. The outlook for the third quarter now looks very similar to the outlook for the second quarter three months ago, with net income growth of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/20/bac-market-outlook-murky-valuations-compelling/83545/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDT) Medical Devices Stock Outlook &#8211; Sept. 2011 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2011/09/08/mdt-medical-devices-stock-outlook-sept-2011-industry-outlook/82743</link>
		<comments>http://www.stockbloghub.com/2011/09/08/mdt-medical-devices-stock-outlook-sept-2011-industry-outlook/82743#comments</comments>
		<pubDate>Thu, 08 Sep 2011 19:53:43 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[Abiomed Inc]]></category>
		<category><![CDATA[ABMD]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton Dickinson Company]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[CNMD]]></category>
		<category><![CDATA[Conmed Corporation]]></category>
		<category><![CDATA[Edwards Lifesciences Corporation]]></category>
		<category><![CDATA[EW]]></category>
		<category><![CDATA[Flaherty & Crumrine Preferred Income Opportunity F]]></category>
		<category><![CDATA[Intuitive Surgical Inc]]></category>
		<category><![CDATA[ISRG]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[PFO]]></category>
		<category><![CDATA[SMA]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>
		<category><![CDATA[Stryker Corporation]]></category>
		<category><![CDATA[SYK]]></category>
		<category><![CDATA[Symmetry Medical Inc]]></category>
		<category><![CDATA[Thermo Fisher Scientific Inc]]></category>
		<category><![CDATA[TMO]]></category>
		<category><![CDATA[VAR]]></category>
		<category><![CDATA[Varian Medical Systems Inc]]></category>
		<category><![CDATA[VOLC]]></category>
		<category><![CDATA[Volcano Corporation]]></category>
		<category><![CDATA[WMGI]]></category>
		<category><![CDATA[Wright Medical Group Inc]]></category>
		<category><![CDATA[Zimmer Holdings Inc]]></category>
		<category><![CDATA[ZMH]]></category>
		<category><![CDATA[ZOLL]]></category>
		<category><![CDATA[Zoll Medical Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=82743</guid>
		<description><![CDATA[June quarter results mostly mirror the preceding quarter as a host of macro headwinds (including price and procedure volume pressures) continued to haunt the MedTech industry and weighed on the performance of the incumbent players. Although a number of these issues are expected to linger over the second-half of 2011, the industry is expected to fare relatively better this year thanks to several tailwinds and growth opportunities. Industry Dynamics The global medical devices industry is fairly large, intensely competitive and highly innovative, with estimated worldwide sales of more than $300 billion in 2011. The U.S. is the largest market, with estimated sales of roughly $95 billion in 2010. The highly-regulated medical devices industry is divided into different segments including Cardiology, Oncology, Neuro, Orthopedic and Aesthetic Devices. The U.S. medical devices ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/08/mdt-medical-devices-stock-outlook-sept-2011-industry-outlook/82743/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GILD) Take Advantage of the Fire Sale in Healthcare</title>
		<link>http://www.stockbloghub.com/2011/08/18/gild-take-advantage-of-the-fire-sale-in-healthcare/81490</link>
		<comments>http://www.stockbloghub.com/2011/08/18/gild-take-advantage-of-the-fire-sale-in-healthcare/81490#comments</comments>
		<pubDate>Fri, 19 Aug 2011 00:47:13 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Kindred Healthcare Inc.]]></category>
		<category><![CDATA[KND]]></category>
		<category><![CDATA[Lexicon Pharmaceuticals Inc]]></category>
		<category><![CDATA[LXRX]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[NUVA]]></category>
		<category><![CDATA[NuVasive Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=81490</guid>
		<description><![CDATA[by Marc Lichtenfeld, Investment U Senior Analyst Wednesday, August 17, 2011: Issue #1580 The market’s violent sell-off over the past two weeks took down many good stocks along with the bad ones. Even with the quick bounce, quality companies are still trading at steep discounts to where they were just two weeks ago and are now at very attractive valuations. This is especially true in the healthcare sector, where names like Gilead Sciences (Nasdaq: GILD), which is down 12 percent, are still below where they were trading prior to the debt crisis decline. Whether the United States’ debt is rated AAA or AA+ should have no bearing on sales of Gilead’s leading HIV drugs or whether its newest drug, Quad, will receive FDA approval. The stock trades at just 11.2 times ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/18/gild-take-advantage-of-the-fire-sale-in-healthcare/81490/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABT) Stock Market News for August 2, 2011 &#8211; Market News</title>
		<link>http://www.stockbloghub.com/2011/08/02/abt-stock-market-news-for-august-2-2011-market-news/80404</link>
		<comments>http://www.stockbloghub.com/2011/08/02/abt-stock-market-news-for-august-2-2011-market-news/80404#comments</comments>
		<pubDate>Tue, 02 Aug 2011 21:22:55 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[AET]]></category>
		<category><![CDATA[Aetna Inc.]]></category>
		<category><![CDATA[BA]]></category>
		<category><![CDATA[Boeing Company]]></category>
		<category><![CDATA[Kratos Defense & Security Solutions Inc]]></category>
		<category><![CDATA[KTOS]]></category>
		<category><![CDATA[LMT]]></category>
		<category><![CDATA[Lockheed Martin Corporation]]></category>
		<category><![CDATA[NOC]]></category>
		<category><![CDATA[Northrop Grumman Corporation]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>
		<category><![CDATA[UNH]]></category>
		<category><![CDATA[Unitedhealth Group Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=80404</guid>
		<description><![CDATA[The benchmarks’ roller-coaster ride finally came to a stop with markets losing modest points, as manufacturing data spoiled the party after Obama and congressional leaders confirmed they had reached an agreement on the debt ceiling. Investor mood swayed from positive to cautious after disappointing ISM data and uncertainty prevailed ahead of the lawmakers vote on the borrowing limit issue. The Dow Jones Industrial Average (DJIA) lost 10 points, or 0.1% to settle at 12,132.49. Earlier the blue-chip index had soared almost 140 points riding on the announcement by President Obama and the congressional heads. However, these gains were washed out by disappointing manufacturing data. The Standard &#38; Poor 500 (S&#38;P 500) shed 0.4% to close at 1,286.94. The Nasdaq Composite Index also lost 0.4% and finished the day at 2,744.61. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/02/abt-stock-market-news-for-august-2-2011-market-news/80404/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMGN) Amgen Beats Earnings Expectations &#8211; Updates Outlook</title>
		<link>http://www.stockbloghub.com/2011/07/30/amgn-amgen-beats-earnings-expectations-updates-outlook/80227</link>
		<comments>http://www.stockbloghub.com/2011/07/30/amgn-amgen-beats-earnings-expectations-updates-outlook/80227#comments</comments>
		<pubDate>Sat, 30 Jul 2011 19:54:20 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[Energy Services of America Corporation]]></category>
		<category><![CDATA[ESA]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=80227</guid>
		<description><![CDATA[Amgen (AMGN) reported second quarter earnings per share of $1.35, 5 cents above the Zacks Consensus Estimate and 0.7% above the year-ago earnings. Total revenues increased 4% to $3,959 million in the second quarter of 2011. Revenues topped the Zacks Consensus Estimate of $3,778 million. US revenues increased 7% during the quarter to $2,975 million. Meanwhile, international revenues increased 11% to $918 million. Foreign exchange (Fx) fluctuation boosted revenues by $34 million during the second quarter. The Quarter in Detail Second quarter total product sales increased 8% to $3,893 million. Revenues of Amgen’s erythropoiesis-stimulating agent (ESA) Aranesp fell 3% to $585 million (US: $241 million, down 10%; ex-US: $344 million, up 2%). US sales were down mainly due to a decline in demand that was partially offset by a price ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/30/amgn-amgen-beats-earnings-expectations-updates-outlook/80227/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AAPL) 2011 Second Quarter Earnings Preview &#8211; Detailed</title>
		<link>http://www.stockbloghub.com/2011/07/18/aapl-2011-second-quarter-earnings-preview-detailed/79251</link>
		<comments>http://www.stockbloghub.com/2011/07/18/aapl-2011-second-quarter-earnings-preview-detailed/79251#comments</comments>
		<pubDate>Mon, 18 Jul 2011 21:09:50 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Personal Computers]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[8x8 Inc]]></category>
		<category><![CDATA[AAPL]]></category>
		<category><![CDATA[ABB]]></category>
		<category><![CDATA[ABB Limited]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Acacia Research Corporation]]></category>
		<category><![CDATA[Acme Packet Inc]]></category>
		<category><![CDATA[ACTG]]></category>
		<category><![CDATA[ADS]]></category>
		<category><![CDATA[Advanced Micro Devices Inc.]]></category>
		<category><![CDATA[AF]]></category>
		<category><![CDATA[Air Products & Chemicals Inc.]]></category>
		<category><![CDATA[Alaska Air Group Inc.]]></category>
		<category><![CDATA[ALB]]></category>
		<category><![CDATA[Albemarle Corporation]]></category>
		<category><![CDATA[Alexion Pharmaceuticals Inc]]></category>
		<category><![CDATA[ALK]]></category>
		<category><![CDATA[Alliance Data Systems Corporation]]></category>
		<category><![CDATA[Altera Corporation]]></category>
		<category><![CDATA[ALTR]]></category>
		<category><![CDATA[Altria Group Inc.]]></category>
		<category><![CDATA[ALV]]></category>
		<category><![CDATA[ALXN]]></category>
		<category><![CDATA[AMD]]></category>
		<category><![CDATA[American Express Company]]></category>
		<category><![CDATA[AmeriServ Financial Inc]]></category>
		<category><![CDATA[Amphenol Corporation]]></category>
		<category><![CDATA[AMR]]></category>
		<category><![CDATA[AMR Corporation]]></category>
		<category><![CDATA[AMSG]]></category>
		<category><![CDATA[AmSurg Corporation]]></category>
		<category><![CDATA[AMTD]]></category>
		<category><![CDATA[AO Smith Corporation]]></category>
		<category><![CDATA[AOS]]></category>
		<category><![CDATA[APD]]></category>
		<category><![CDATA[APH]]></category>
		<category><![CDATA[APKT]]></category>
		<category><![CDATA[Apple Inc.]]></category>
		<category><![CDATA[AptarGroup Inc.]]></category>
		<category><![CDATA[ARB]]></category>
		<category><![CDATA[Arbitron Inc]]></category>
		<category><![CDATA[ASBC]]></category>
		<category><![CDATA[ASR]]></category>
		<category><![CDATA[ASRV]]></category>
		<category><![CDATA[Associated Banc-Corp]]></category>
		<category><![CDATA[Astoria Financial Corporation]]></category>
		<category><![CDATA[AT Cross Company]]></category>
		<category><![CDATA[AT&T Inc.]]></category>
		<category><![CDATA[Athenahealth Inc]]></category>
		<category><![CDATA[ATHN]]></category>
		<category><![CDATA[ATMI]]></category>
		<category><![CDATA[ATMI Inc.]]></category>
		<category><![CDATA[ATR]]></category>
		<category><![CDATA[ATX]]></category>
		<category><![CDATA[Autoliv Inc.]]></category>
		<category><![CDATA[AVID]]></category>
		<category><![CDATA[Avid Technology Inc]]></category>
		<category><![CDATA[AXP]]></category>
		<category><![CDATA[BAC]]></category>
		<category><![CDATA[Badger Meter Inc]]></category>
		<category><![CDATA[BancFirst Corporation]]></category>
		<category><![CDATA[Banco Latinoamericano de Exportaciones SA]]></category>
		<category><![CDATA[Bancorp Rhode Island Inc]]></category>
		<category><![CDATA[BANF]]></category>
		<category><![CDATA[Bank of America Corporation]]></category>
		<category><![CDATA[Banner Corporation]]></category>
		<category><![CDATA[BANR]]></category>
		<category><![CDATA[BARI]]></category>
		<category><![CDATA[BAS]]></category>
		<category><![CDATA[Basic Energy Services Inc.]]></category>
		<category><![CDATA[BAX]]></category>
		<category><![CDATA[Baxter International Inc]]></category>
		<category><![CDATA[BB & T Corporation]]></category>
		<category><![CDATA[BBT]]></category>
		<category><![CDATA[BJ's Restaurants Inc.]]></category>
		<category><![CDATA[BJRI]]></category>
		<category><![CDATA[BK]]></category>
		<category><![CDATA[BlackRock Inc.]]></category>
		<category><![CDATA[BLDR]]></category>
		<category><![CDATA[BLK]]></category>
		<category><![CDATA[BLX]]></category>
		<category><![CDATA[BMI]]></category>
		<category><![CDATA[BOOT]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BPOP]]></category>
		<category><![CDATA[BRO]]></category>
		<category><![CDATA[Brown & Brown Inc.]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[BTU]]></category>
		<category><![CDATA[Builders FirstSource Inc]]></category>
		<category><![CDATA[BX]]></category>
		<category><![CDATA[CA]]></category>
		<category><![CDATA[Ca Technologies]]></category>
		<category><![CDATA[CAKE]]></category>
		<category><![CDATA[Cardinal Financial Corporation]]></category>
		<category><![CDATA[Cash America International Inc]]></category>
		<category><![CDATA[CAT]]></category>
		<category><![CDATA[Caterpillar Inc.]]></category>
		<category><![CDATA[Cathay General Bancorp]]></category>
		<category><![CDATA[CATY]]></category>
		<category><![CDATA[CB]]></category>
		<category><![CDATA[CBE]]></category>
		<category><![CDATA[CBI]]></category>
		<category><![CDATA[CCK]]></category>
		<category><![CDATA[CE]]></category>
		<category><![CDATA[Celanese Corporation]]></category>
		<category><![CDATA[Celestica Inc.]]></category>
		<category><![CDATA[Cemex S.A.B. de C.V.]]></category>
		<category><![CDATA[Central Valley Community Bancorp]]></category>
		<category><![CDATA[Cepheid]]></category>
		<category><![CDATA[CFNL]]></category>
		<category><![CDATA[Charles Schwab Corporation]]></category>
		<category><![CDATA[Check Point Software Technologies Limited]]></category>
		<category><![CDATA[Chicago Bridge & Iron Company N.V.]]></category>
		<category><![CDATA[Chipotle Mexican Grill Inc.]]></category>
		<category><![CDATA[CHKP]]></category>
		<category><![CDATA[Cintas Corporation]]></category>
		<category><![CDATA[Cirrus Logic Inc.]]></category>
		<category><![CDATA[City National Corporation]]></category>
		<category><![CDATA[CLB]]></category>
		<category><![CDATA[CLS]]></category>
		<category><![CDATA[CMA]]></category>
		<category><![CDATA[CMCO]]></category>
		<category><![CDATA[CMG]]></category>
		<category><![CDATA[CNS]]></category>
		<category><![CDATA[CoBiz Financial Inc]]></category>
		<category><![CDATA[COBZ]]></category>
		<category><![CDATA[Coca-Cola FEMSA S.A.B de CV]]></category>
		<category><![CDATA[Cohen & Steers Inc.]]></category>
		<category><![CDATA[COHU]]></category>
		<category><![CDATA[Cohu Inc]]></category>
		<category><![CDATA[COL]]></category>
		<category><![CDATA[Columbus Mckinnon Corporation]]></category>
		<category><![CDATA[Comerica Incorporated]]></category>
		<category><![CDATA[Complete Production Services Inc]]></category>
		<category><![CDATA[Compuware Corporation]]></category>
		<category><![CDATA[Cooper Industries Limited]]></category>
		<category><![CDATA[Core Laboratories NV]]></category>
		<category><![CDATA[Covanta Holding Corporation]]></category>
		<category><![CDATA[CPHD]]></category>
		<category><![CDATA[CPWR]]></category>
		<category><![CDATA[CPX]]></category>
		<category><![CDATA[Crown Holdings Inc.]]></category>
		<category><![CDATA[CRUS]]></category>
		<category><![CDATA[CSH]]></category>
		<category><![CDATA[CSX]]></category>
		<category><![CDATA[CSX Corporation]]></category>
		<category><![CDATA[CTAS]]></category>
		<category><![CDATA[CVA]]></category>
		<category><![CDATA[CVB Financial Corporation]]></category>
		<category><![CDATA[CVBF]]></category>
		<category><![CDATA[CVCY]]></category>
		<category><![CDATA[CX]]></category>
		<category><![CDATA[CY]]></category>
		<category><![CDATA[Cymer Inc.]]></category>
		<category><![CDATA[CYMI]]></category>
		<category><![CDATA[CYN]]></category>
		<category><![CDATA[Cypress Semiconductor Corporation]]></category>
		<category><![CDATA[CYT]]></category>
		<category><![CDATA[Cytec Industries Inc.]]></category>
		<category><![CDATA[DAL]]></category>
		<category><![CDATA[Danaher Corporation]]></category>
		<category><![CDATA[Datalink Corporation]]></category>
		<category><![CDATA[Delta Air Lines Inc.]]></category>
		<category><![CDATA[DGII]]></category>
		<category><![CDATA[DGX]]></category>
		<category><![CDATA[DHR]]></category>
		<category><![CDATA[Diamond Offshore Drilling Inc]]></category>
		<category><![CDATA[Digi International Inc.]]></category>
		<category><![CDATA[DO]]></category>
		<category><![CDATA[DOV]]></category>
		<category><![CDATA[Dover Corporation]]></category>
		<category><![CDATA[DTLK]]></category>
		<category><![CDATA[E*TRADE Financial Corporation]]></category>
		<category><![CDATA[Eagle Bancorp Inc]]></category>
		<category><![CDATA[East West Bancorp Inc]]></category>
		<category><![CDATA[Eastern Virginia Bankshares Inc]]></category>
		<category><![CDATA[EastGroup Properties Inc]]></category>
		<category><![CDATA[EBAY]]></category>
		<category><![CDATA[eBay Inc.]]></category>
		<category><![CDATA[ECA]]></category>
		<category><![CDATA[EDR]]></category>
		<category><![CDATA[EDU]]></category>
		<category><![CDATA[Education Realty Trust Inc]]></category>
		<category><![CDATA[Edwards Lifesciences Corporation]]></category>
		<category><![CDATA[EFII]]></category>
		<category><![CDATA[EGBN]]></category>
		<category><![CDATA[EGHT]]></category>
		<category><![CDATA[EGP]]></category>
		<category><![CDATA[Electronics for Imaging Inc.]]></category>
		<category><![CDATA[ELGX]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[ELS]]></category>
		<category><![CDATA[EMC]]></category>
		<category><![CDATA[EMC Corporation]]></category>
		<category><![CDATA[Encana Corporation]]></category>
		<category><![CDATA[Endologix Inc]]></category>
		<category><![CDATA[Entegris Inc]]></category>
		<category><![CDATA[ENTG]]></category>
		<category><![CDATA[Equity Lifestyles Properties Inc]]></category>
		<category><![CDATA[ERIC]]></category>
		<category><![CDATA[ESI]]></category>
		<category><![CDATA[ETFC]]></category>
		<category><![CDATA[EVBS]]></category>
		<category><![CDATA[EW]]></category>
		<category><![CDATA[EWBC]]></category>
		<category><![CDATA[EXPO]]></category>
		<category><![CDATA[Exponent Inc.]]></category>
		<category><![CDATA[EZCORP Inc.]]></category>
		<category><![CDATA[EZPW]]></category>
		<category><![CDATA[F5 Networks Inc.]]></category>
		<category><![CDATA[FCFS]]></category>
		<category><![CDATA[FCX]]></category>
		<category><![CDATA[FFIV]]></category>
		<category><![CDATA[Fidelity National Information Services Inc]]></category>
		<category><![CDATA[Fifth Third Bancorp]]></category>
		<category><![CDATA[First Cash Financial Services Inc]]></category>
		<category><![CDATA[First Niagara Financial Group Inc]]></category>
		<category><![CDATA[FIS]]></category>
		<category><![CDATA[FITB]]></category>
		<category><![CDATA[FLEX]]></category>
		<category><![CDATA[Flextronics International Limited]]></category>
		<category><![CDATA[FLIR]]></category>
		<category><![CDATA[FLIR Systems Inc]]></category>
		<category><![CDATA[FMX]]></category>
		<category><![CDATA[FNFG]]></category>
		<category><![CDATA[Fomento Economico Mexicano S.a.b De C.v.]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[Forward Air Corporation]]></category>
		<category><![CDATA[Freeport-McMoRan Copper & Gold Inc]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[FULT]]></category>
		<category><![CDATA[Fulton Financial Corporation]]></category>
		<category><![CDATA[FWRD]]></category>
		<category><![CDATA[Gannett Company Inc]]></category>
		<category><![CDATA[Gardner Denver Inc.]]></category>
		<category><![CDATA[GCI]]></category>
		<category><![CDATA[GDI]]></category>
		<category><![CDATA[GE]]></category>
		<category><![CDATA[General Electric Company]]></category>
		<category><![CDATA[Gentex Corporation]]></category>
		<category><![CDATA[GLF]]></category>
		<category><![CDATA[Glimcher Realty Trust]]></category>
		<category><![CDATA[Global Payments Inc]]></category>
		<category><![CDATA[GNTX]]></category>
		<category><![CDATA[Goldman Sachs Group]]></category>
		<category><![CDATA[Goodrich Corporation]]></category>
		<category><![CDATA[GPN]]></category>
		<category><![CDATA[GR]]></category>
		<category><![CDATA[GRT]]></category>
		<category><![CDATA[Grupo Aeroportuario Centro Norte S.A. de C.V.]]></category>
		<category><![CDATA[Grupo Aeroportuario Del Sureste SA de CV]]></category>
		<category><![CDATA[GS]]></category>
		<category><![CDATA[Gulfmark Offshore Inc.]]></category>
		<category><![CDATA[GWW]]></category>
		<category><![CDATA[HAFC]]></category>
		<category><![CDATA[HAL]]></category>
		<category><![CDATA[Halliburton Company]]></category>
		<category><![CDATA[Hancock Holding Company]]></category>
		<category><![CDATA[Hanesbrands Inc.]]></category>
		<category><![CDATA[Hanmi Financial Corporation]]></category>
		<category><![CDATA[Harley-Davidson Inc.]]></category>
		<category><![CDATA[HAS]]></category>
		<category><![CDATA[Hasbro Inc.]]></category>
		<category><![CDATA[HBAN]]></category>
		<category><![CDATA[HBHC]]></category>
		<category><![CDATA[HBI]]></category>
		<category><![CDATA[Healthways Inc]]></category>
		<category><![CDATA[Heartland Express Inc]]></category>
		<category><![CDATA[HGSI]]></category>
		<category><![CDATA[HITT]]></category>
		<category><![CDATA[Hittite Microwave Corporation]]></category>
		<category><![CDATA[HNI]]></category>
		<category><![CDATA[HNI Corporation]]></category>
		<category><![CDATA[HOG]]></category>
		<category><![CDATA[HOMB]]></category>
		<category><![CDATA[Home Bancshares Inc (Conway AR)]]></category>
		<category><![CDATA[HON]]></category>
		<category><![CDATA[Honeywell International Inc.]]></category>
		<category><![CDATA[Host Hotels & Resorts Inc.]]></category>
		<category><![CDATA[HST]]></category>
		<category><![CDATA[HTLD]]></category>
		<category><![CDATA[Human Genome Sciences Inc.]]></category>
		<category><![CDATA[Huntington Bancshares Inc]]></category>
		<category><![CDATA[HWAY]]></category>
		<category><![CDATA[IBKR]]></category>
		<category><![CDATA[IBM]]></category>
		<category><![CDATA[ICLR]]></category>
		<category><![CDATA[ICON plc]]></category>
		<category><![CDATA[ICU Medical Inc]]></category>
		<category><![CDATA[ICUI]]></category>
		<category><![CDATA[IDEX Corporation]]></category>
		<category><![CDATA[IDEXX Laboratories Inc.]]></category>
		<category><![CDATA[IDXX]]></category>
		<category><![CDATA[IEX]]></category>
		<category><![CDATA[IIIN]]></category>
		<category><![CDATA[INFA]]></category>
		<category><![CDATA[Infinera Corporation]]></category>
		<category><![CDATA[INFN]]></category>
		<category><![CDATA[Informatica Corporation]]></category>
		<category><![CDATA[Ingersoll-Rand Company Limited]]></category>
		<category><![CDATA[Insteel Industries Inc.]]></category>
		<category><![CDATA[INTC]]></category>
		<category><![CDATA[Intel Corporation]]></category>
		<category><![CDATA[Interactive Brokers Group Inc]]></category>
		<category><![CDATA[International Business Machines]]></category>
		<category><![CDATA[Intuitive Surgical Inc]]></category>
		<category><![CDATA[IR]]></category>
		<category><![CDATA[ISRG]]></category>
		<category><![CDATA[ITT Educational Services Inc.]]></category>
		<category><![CDATA[Ixia]]></category>
		<category><![CDATA[JAKK]]></category>
		<category><![CDATA[JAKKS Pacific Inc.]]></category>
		<category><![CDATA[Janus Capital Group Inc.]]></category>
		<category><![CDATA[JCI]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[JNS]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Johnson Controls Inc.]]></category>
		<category><![CDATA[Kansas City Southern]]></category>
		<category><![CDATA[Kayne Anderson Energy Development Company]]></category>
		<category><![CDATA[KED]]></category>
		<category><![CDATA[KEY]]></category>
		<category><![CDATA[KeyCorp]]></category>
		<category><![CDATA[Kinder Morgan Energy Partners LP]]></category>
		<category><![CDATA[Kinder Morgan Management LLC]]></category>
		<category><![CDATA[KMP]]></category>
		<category><![CDATA[KMR]]></category>
		<category><![CDATA[KNL]]></category>
		<category><![CDATA[Knoll Inc.]]></category>
		<category><![CDATA[KO]]></category>
		<category><![CDATA[KOF]]></category>
		<category><![CDATA[KSU]]></category>
		<category><![CDATA[Laboratory Corporation of America Holdings]]></category>
		<category><![CDATA[Lacrosse Footwear Inc.]]></category>
		<category><![CDATA[Landstar System Inc.]]></category>
		<category><![CDATA[Lare Holdings Inc]]></category>
		<category><![CDATA[LaSalle Hotel Properties]]></category>
		<category><![CDATA[Lattice Semiconductor Corporation]]></category>
		<category><![CDATA[LCC]]></category>
		<category><![CDATA[LECO]]></category>
		<category><![CDATA[LH]]></category>
		<category><![CDATA[LHO]]></category>
		<category><![CDATA[Life Time Fitness Inc.]]></category>
		<category><![CDATA[Lincoln Electric Holdings]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Lm Ericsson Telephone Company]]></category>
		<category><![CDATA[LNCR]]></category>
		<category><![CDATA[LSCC]]></category>
		<category><![CDATA[LSTR]]></category>
		<category><![CDATA[LTM]]></category>
		<category><![CDATA[LUFK]]></category>
		<category><![CDATA[Lufkin Industries Inc.]]></category>
		<category><![CDATA[M&T Bank Corporation]]></category>
		<category><![CDATA[MAN]]></category>
		<category><![CDATA[MANH]]></category>
		<category><![CDATA[Manhattan Associates Inc.]]></category>
		<category><![CDATA[Manpower Inc.]]></category>
		<category><![CDATA[Marten Transport Limited]]></category>
		<category><![CDATA[Matthews International Corporation]]></category>
		<category><![CDATA[MATW]]></category>
		<category><![CDATA[Mb Financial Inc]]></category>
		<category><![CDATA[MBFI]]></category>
		<category><![CDATA[MBWM]]></category>
		<category><![CDATA[MCBI]]></category>
		<category><![CDATA[MCD]]></category>
		<category><![CDATA[McDonald's Corporation]]></category>
		<category><![CDATA[McMoRan Exploration Company]]></category>
		<category><![CDATA[MCRI]]></category>
		<category><![CDATA[MedcoHealth Solutions Inc.]]></category>
		<category><![CDATA[Mellanox Technologies Limited]]></category>
		<category><![CDATA[Mercantile Bank Corporation]]></category>
		<category><![CDATA[Meridian Bioscience Inc.]]></category>
		<category><![CDATA[Merit Medical Systems Inc]]></category>
		<category><![CDATA[Metrocorp Bancshares Inc.]]></category>
		<category><![CDATA[MGIC Investment Corporation]]></category>
		<category><![CDATA[MHS]]></category>
		<category><![CDATA[Microsoft Corporation]]></category>
		<category><![CDATA[MKS Instruments Inc.]]></category>
		<category><![CDATA[MKSI]]></category>
		<category><![CDATA[MLNX]]></category>
		<category><![CDATA[MMR]]></category>
		<category><![CDATA[MMSI]]></category>
		<category><![CDATA[MNRO]]></category>
		<category><![CDATA[MO]]></category>
		<category><![CDATA[MOH]]></category>
		<category><![CDATA[Molina Healthcare Inc.]]></category>
		<category><![CDATA[Monarch Casino & Resort Inc.]]></category>
		<category><![CDATA[Monro Muffler Brake Inc.]]></category>
		<category><![CDATA[Morgan Stanley]]></category>
		<category><![CDATA[MOS]]></category>
		<category><![CDATA[Mosaic Company]]></category>
		<category><![CDATA[MOSY]]></category>
		<category><![CDATA[MoSys Inc]]></category>
		<category><![CDATA[MRTN]]></category>
		<category><![CDATA[MS]]></category>
		<category><![CDATA[MSFT]]></category>
		<category><![CDATA[MTB]]></category>
		<category><![CDATA[MTG]]></category>
		<category><![CDATA[MYE]]></category>
		<category><![CDATA[Myers Industries Inc.]]></category>
		<category><![CDATA[NAFC]]></category>
		<category><![CDATA[Nash FInch Company]]></category>
		<category><![CDATA[NCR]]></category>
		<category><![CDATA[NCR Corporation]]></category>
		<category><![CDATA[NE]]></category>
		<category><![CDATA[NetScout Systems Inc]]></category>
		<category><![CDATA[New Oriental Education & Technology Group]]></category>
		<category><![CDATA[New York Community Bancorp Inc]]></category>
		<category><![CDATA[Newfield Exploration Company]]></category>
		<category><![CDATA[NFX]]></category>
		<category><![CDATA[Noble Corporation]]></category>
		<category><![CDATA[NOK]]></category>
		<category><![CDATA[Nokia Corporation]]></category>
		<category><![CDATA[Northern Trust Corporation]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NTCT]]></category>
		<category><![CDATA[NTRS]]></category>
		<category><![CDATA[Nucor Corporation]]></category>
		<category><![CDATA[NUE]]></category>
		<category><![CDATA[NVE Corporation]]></category>
		<category><![CDATA[NVEC]]></category>
		<category><![CDATA[NVR]]></category>
		<category><![CDATA[NVR Inc.]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[NYB]]></category>
		<category><![CDATA[NYT]]></category>
		<category><![CDATA[OceanFirst Financial Corporation]]></category>
		<category><![CDATA[OCFC]]></category>
		<category><![CDATA[OFG]]></category>
		<category><![CDATA[Old Republic International Corporation]]></category>
		<category><![CDATA[Olin Corporation]]></category>
		<category><![CDATA[OLN]]></category>
		<category><![CDATA[OMAB]]></category>
		<category><![CDATA[OMC]]></category>
		<category><![CDATA[Omnicom Group Inc.]]></category>
		<category><![CDATA[ORI]]></category>
		<category><![CDATA[Oriental Financial Group Inc.]]></category>
		<category><![CDATA[Pacific Continental Corporation]]></category>
		<category><![CDATA[Packaging Corporation of America]]></category>
		<category><![CDATA[PAG]]></category>
		<category><![CDATA[Park National Corporation]]></category>
		<category><![CDATA[PBCT]]></category>
		<category><![CDATA[PCBK]]></category>
		<category><![CDATA[PCP]]></category>
		<category><![CDATA[PDS]]></category>
		<category><![CDATA[Peabody Energy Corporation]]></category>
		<category><![CDATA[PENN]]></category>
		<category><![CDATA[Penn National Gaming Inc.]]></category>
		<category><![CDATA[Penske Automotive Group Inc.]]></category>
		<category><![CDATA[Peoples United Financial Inc]]></category>
		<category><![CDATA[PEP]]></category>
		<category><![CDATA[Pepsico Inc.]]></category>
		<category><![CDATA[PetMed Express Inc.]]></category>
		<category><![CDATA[PETS]]></category>
		<category><![CDATA[PGI]]></category>
		<category><![CDATA[Philip Morris International Inc]]></category>
		<category><![CDATA[PII]]></category>
		<category><![CDATA[Pinnacle Financial Partners Inc]]></category>
		<category><![CDATA[Piper Jaffray Companies]]></category>
		<category><![CDATA[PJC]]></category>
		<category><![CDATA[PKG]]></category>
		<category><![CDATA[Platinum Underwriters Holdings Limited]]></category>
		<category><![CDATA[PLCM]]></category>
		<category><![CDATA[Plexus Corporation]]></category>
		<category><![CDATA[PLXS]]></category>
		<category><![CDATA[PM]]></category>
		<category><![CDATA[PMC-Sierra Inc.]]></category>
		<category><![CDATA[PMCS]]></category>
		<category><![CDATA[PNC]]></category>
		<category><![CDATA[PNC Financial Services Group Inc]]></category>
		<category><![CDATA[PNFP]]></category>
		<category><![CDATA[Polaris Industries Inc.]]></category>
		<category><![CDATA[Polycom Inc.]]></category>
		<category><![CDATA[POOL]]></category>
		<category><![CDATA[Pool Corp]]></category>
		<category><![CDATA[Popular Inc]]></category>
		<category><![CDATA[PPG]]></category>
		<category><![CDATA[PPG Industries Inc.]]></category>
		<category><![CDATA[Precision Castparts Corporation]]></category>
		<category><![CDATA[Precision Drilling Trust]]></category>
		<category><![CDATA[Premiere Global Services Inc.]]></category>
		<category><![CDATA[PRK]]></category>
		<category><![CDATA[Prosperity Bancshares Inc.]]></category>
		<category><![CDATA[PRSP]]></category>
		<category><![CDATA[PTP]]></category>
		<category><![CDATA[QCOM]]></category>
		<category><![CDATA[QUALCOMM Inc]]></category>
		<category><![CDATA[Quest Diagnostics Inc.]]></category>
		<category><![CDATA[RAI]]></category>
		<category><![CDATA[Raymond James Financial Inc.]]></category>
		<category><![CDATA[Renaissance Learning Inc.]]></category>
		<category><![CDATA[Renasant Corporation]]></category>
		<category><![CDATA[Reynolds American Inc.]]></category>
		<category><![CDATA[RHI]]></category>
		<category><![CDATA[Riverbed Technology Inc.]]></category>
		<category><![CDATA[RJF]]></category>
		<category><![CDATA[RLI]]></category>
		<category><![CDATA[RLI Corporation]]></category>
		<category><![CDATA[RLRN]]></category>
		<category><![CDATA[RNST]]></category>
		<category><![CDATA[Robert Half International Inc.]]></category>
		<category><![CDATA[Rockwell Collins Inc.]]></category>
		<category><![CDATA[RRR]]></category>
		<category><![CDATA[RSC Holdings Inc.]]></category>
		<category><![CDATA[RT]]></category>
		<category><![CDATA[Ruby Tuesday Inc.]]></category>
		<category><![CDATA[RVBD]]></category>
		<category><![CDATA[SABA]]></category>
		<category><![CDATA[Saba Software Inc.]]></category>
		<category><![CDATA[Safeway Inc.]]></category>
		<category><![CDATA[SanDisk Corporation]]></category>
		<category><![CDATA[Sandy Spring Bancorp Inc]]></category>
		<category><![CDATA[SASR]]></category>
		<category><![CDATA[SBIB]]></category>
		<category><![CDATA[Schiff Nutrition International Inc]]></category>
		<category><![CDATA[SCHL]]></category>
		<category><![CDATA[Schlumberger Limited]]></category>
		<category><![CDATA[Scholastic Corporation]]></category>
		<category><![CDATA[SCHW]]></category>
		<category><![CDATA[SCSS]]></category>
		<category><![CDATA[Seagate Technology]]></category>
		<category><![CDATA[SEI Investments Company]]></category>
		<category><![CDATA[SEIC]]></category>
		<category><![CDATA[Select Comfort Corporation]]></category>
		<category><![CDATA[Sensient Technologies Corporation]]></category>
		<category><![CDATA[SFG]]></category>
		<category><![CDATA[SFNC]]></category>
		<category><![CDATA[Sherwin-Williams Company]]></category>
		<category><![CDATA[SHW]]></category>
		<category><![CDATA[Simmons First National Corporation]]></category>
		<category><![CDATA[Skyworks Solutions Inc.]]></category>
		<category><![CDATA[SLB]]></category>
		<category><![CDATA[SLM]]></category>
		<category><![CDATA[Slm Corporation]]></category>
		<category><![CDATA[SNA]]></category>
		<category><![CDATA[Snap-on Inc.]]></category>
		<category><![CDATA[SNDK]]></category>
		<category><![CDATA[SON]]></category>
		<category><![CDATA[Sonoco Products Company]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[StanCorp Financial Group Inc.]]></category>
		<category><![CDATA[Stanley Black & Decker]]></category>
		<category><![CDATA[Stanley Furniture Company Inc]]></category>
		<category><![CDATA[State Street Corporation]]></category>
		<category><![CDATA[Steel Dynamics Inc.]]></category>
		<category><![CDATA[Sterling Bancshares Inc]]></category>
		<category><![CDATA[STI]]></category>
		<category><![CDATA[STJ]]></category>
		<category><![CDATA[STLD]]></category>
		<category><![CDATA[STLY]]></category>
		<category><![CDATA[Stryker Corporation]]></category>
		<category><![CDATA[STT]]></category>
		<category><![CDATA[STX]]></category>
		<category><![CDATA[SunTrust Banks Inc.]]></category>
		<category><![CDATA[SWK]]></category>
		<category><![CDATA[SWKS]]></category>
		<category><![CDATA[SWY]]></category>
		<category><![CDATA[SXT]]></category>
		<category><![CDATA[SY Bancorp Inc.]]></category>
		<category><![CDATA[SYBT]]></category>
		<category><![CDATA[SYK]]></category>
		<category><![CDATA[T]]></category>
		<category><![CDATA[Taubman Centers Inc.]]></category>
		<category><![CDATA[TAYC]]></category>
		<category><![CDATA[Taylor Capital Group Inc]]></category>
		<category><![CDATA[TBBK]]></category>
		<category><![CDATA[TCB]]></category>
		<category><![CDATA[TCBI]]></category>
		<category><![CDATA[TCF Financial Corporation]]></category>
		<category><![CDATA[TCO]]></category>
		<category><![CDATA[TD AMERITRADE Holding Corporation]]></category>
		<category><![CDATA[TEL]]></category>
		<category><![CDATA[Temple-Inland Inc.]]></category>
		<category><![CDATA[Terex Corporation]]></category>
		<category><![CDATA[TESS]]></category>
		<category><![CDATA[TESSCO Technologies Inc.]]></category>
		<category><![CDATA[TEX]]></category>
		<category><![CDATA[Texas Capital BancShares Inc.]]></category>
		<category><![CDATA[Textron Inc.]]></category>
		<category><![CDATA[The Bancorp Inc]]></category>
		<category><![CDATA[The Bank of New York Mellon Corporation]]></category>
		<category><![CDATA[The Blackstone Group]]></category>
		<category><![CDATA[The Cheesecake Factory Incorporated]]></category>
		<category><![CDATA[The Chubb Corporation]]></category>
		<category><![CDATA[The Coca-Cola Company]]></category>
		<category><![CDATA[The New York Times Company]]></category>
		<category><![CDATA[The Travelers Companies Inc.]]></category>
		<category><![CDATA[Thomas & Betts Corporation]]></category>
		<category><![CDATA[TIN]]></category>
		<category><![CDATA[TNB]]></category>
		<category><![CDATA[Tractor Supply Company]]></category>
		<category><![CDATA[TRIB]]></category>
		<category><![CDATA[Trinity Biotech plc]]></category>
		<category><![CDATA[TRV]]></category>
		<category><![CDATA[TSCO]]></category>
		<category><![CDATA[TXT]]></category>
		<category><![CDATA[Tyco Electronics Limited]]></category>
		<category><![CDATA[UAL]]></category>
		<category><![CDATA[UBNK]]></category>
		<category><![CDATA[Ultratech Inc.]]></category>
		<category><![CDATA[UMPQ]]></category>
		<category><![CDATA[Umpqua Holdings Corporation]]></category>
		<category><![CDATA[UNH]]></category>
		<category><![CDATA[Union Pacific Corporation]]></category>
		<category><![CDATA[United Continental Holdings]]></category>
		<category><![CDATA[United Financial Bancorp]]></category>
		<category><![CDATA[United Rentals Inc]]></category>
		<category><![CDATA[United Technologies Corporation]]></category>
		<category><![CDATA[Unitedhealth Group Inc.]]></category>
		<category><![CDATA[UNP]]></category>
		<category><![CDATA[URI]]></category>
		<category><![CDATA[US Airways Group Inc.]]></category>
		<category><![CDATA[Us Bancorp]]></category>
		<category><![CDATA[USB]]></category>
		<category><![CDATA[UTEK]]></category>
		<category><![CDATA[UTX]]></category>
		<category><![CDATA[VCBI]]></category>
		<category><![CDATA[Verizon Communications Inc.]]></category>
		<category><![CDATA[VF Corporation]]></category>
		<category><![CDATA[VFC]]></category>
		<category><![CDATA[Virginia Commerce Bancorp Inc]]></category>
		<category><![CDATA[Vitran Corp Inc]]></category>
		<category><![CDATA[VIVO]]></category>
		<category><![CDATA[VMW]]></category>
		<category><![CDATA[VMware Inc.]]></category>
		<category><![CDATA[VTNC]]></category>
		<category><![CDATA[VZ]]></category>
		<category><![CDATA[W.W. Grainger Inc]]></category>
		<category><![CDATA[WABC]]></category>
		<category><![CDATA[WAL]]></category>
		<category><![CDATA[Waste Connections Inc.]]></category>
		<category><![CDATA[Watsco Inc.]]></category>
		<category><![CDATA[WCC]]></category>
		<category><![CDATA[WCN]]></category>
		<category><![CDATA[WDC]]></category>
		<category><![CDATA[Wells Fargo & Company]]></category>
		<category><![CDATA[WERN]]></category>
		<category><![CDATA[Werner Enterprises Inc.]]></category>
		<category><![CDATA[WESCO International Inc.]]></category>
		<category><![CDATA[Westamerica BanCorporation]]></category>
		<category><![CDATA[Westell Technologies Inc]]></category>
		<category><![CDATA[Western Alliance Bancorporation]]></category>
		<category><![CDATA[Western Digital Corporation]]></category>
		<category><![CDATA[Westwood Holdings Group Inc]]></category>
		<category><![CDATA[WFC]]></category>
		<category><![CDATA[WHG]]></category>
		<category><![CDATA[Whirlpool Corporation]]></category>
		<category><![CDATA[WHR]]></category>
		<category><![CDATA[Wipro Limited]]></category>
		<category><![CDATA[WIT]]></category>
		<category><![CDATA[WNI]]></category>
		<category><![CDATA[WNS]]></category>
		<category><![CDATA[WNS (Holdings) Limited]]></category>
		<category><![CDATA[WSO]]></category>
		<category><![CDATA[WSTL]]></category>
		<category><![CDATA[WYNN]]></category>
		<category><![CDATA[Wynn Resorts Limited]]></category>
		<category><![CDATA[Xerox Corporation]]></category>
		<category><![CDATA[Xilinx Inc.]]></category>
		<category><![CDATA[XLNX]]></category>
		<category><![CDATA[XRX]]></category>
		<category><![CDATA[XXIA]]></category>
		<category><![CDATA[Yahoo! Inc.]]></category>
		<category><![CDATA[YHOO]]></category>
		<category><![CDATA[ZION]]></category>
		<category><![CDATA[Zions BanCorporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=79251</guid>
		<description><![CDATA[Earnings Preview 7/15/11 Second quarter earnings season is now under way, but things really start to move into high gear next week. There will be 348 firms reporting, and 108 of those are in the S&#38;P 500. By next Friday we should have a very good handle on how the overall earnings season will go. The firms reporting this week are sort of like a who&#8217;s who of U.S. industry including: Apple (AAPL), American Express (AXP), Bank of America (BAC), Caterpillar (CAT), General Electric (GE), International Business Machines (IBM), Intel (INTC), McDonald&#8217;s (MCD), Schlumberger (SLB) and Verizon (VZ). That is an interesting cross section of U.S. business. We have a relatively light economic data calendar, so earnings should be front and center, along with the sovereign debt situations on both ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/18/aapl-2011-second-quarter-earnings-preview-detailed/79251/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SRDX) SurModics Analysts Cut Shares to Neutral</title>
		<link>http://www.stockbloghub.com/2011/07/10/srdx-surmodics-analysts-cut-shares-to-neutral/78588</link>
		<comments>http://www.stockbloghub.com/2011/07/10/srdx-surmodics-analysts-cut-shares-to-neutral/78588#comments</comments>
		<pubDate>Sun, 10 Jul 2011 18:17:57 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[SRDX]]></category>
		<category><![CDATA[SurModics Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78588</guid>
		<description><![CDATA[We are downgrading SurModics (SRDX) to Neutral from Outperform following its setback, when partner Johnson &#38; Johnson (JNJ) announced in June 2011 that it will stop manufacturing Cypher and Cypher Select Plus sirolimus-eluting coronary stents by year-end. SurModics receives royalties on sales of the product. The news impacted SurModics’ shares negatively. We too have slashed our earnings estimate for fiscal 2012 by $0.08 per share. However, management at SurModics is not too perturbed by the recent development since royalties from the sales of Cypher stent have been on the decline due to reduced sales of the product. Sales of the product have been on the decline due to increased completion from players like Abbott Labs (ABT), Medtronic Inc. (MDT) and Boston Scientific Corporation (BSX). Global sales of Cypher during the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/10/srdx-surmodics-analysts-cut-shares-to-neutral/78588/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYGN) Myriad Genetics Analyst Uprades Shares to Outperform</title>
		<link>http://www.stockbloghub.com/2011/07/01/mygn-myriad-genetics-analyst-uprades-shares-to-outperform/78154</link>
		<comments>http://www.stockbloghub.com/2011/07/01/mygn-myriad-genetics-analyst-uprades-shares-to-outperform/78154#comments</comments>
		<pubDate>Fri, 01 Jul 2011 16:39:43 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[MYGN]]></category>
		<category><![CDATA[Myriad Genetics Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78154</guid>
		<description><![CDATA[Recently, we upgraded Myriad Genetics (MYGN) to Outperform with a target price of $27.00. Myriad is confident of retaining the momentum recorded over the past few quarters going ahead through product portfolio expansion, targeting the companion diagnostic market and expansion into Europe. With respect to new products, Myriad aims to launch at least one new molecular diagnostic product each year. The company’s tenth product, slated for launch in the second half of 2011, will assist dermatopathologists in determining whether a patient’s mole is benign or a malignant melanoma. We are also encouraged by Myriad’s recent acquisition of Texas based, privately-held Rules-Based Medicine (RBM) for $80 million in cash. This deal would expand the company’s portfolio to take into its ambit psychiatric disorders, infectious diseases and inflammatory diseases. According to Myriad, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/01/mygn-myriad-genetics-analyst-uprades-shares-to-outperform/78154/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABT) Abbott Labs and Reata Pharmaceuticals Present New Phase II Data</title>
		<link>http://www.stockbloghub.com/2011/06/29/abt-abbott-labs-and-reata-pharmaceuticals-present-new-phase-ii-data/77768</link>
		<comments>http://www.stockbloghub.com/2011/06/29/abt-abbott-labs-and-reata-pharmaceuticals-present-new-phase-ii-data/77768#comments</comments>
		<pubDate>Wed, 29 Jun 2011 16:43:51 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Marshall & Ilsley Corporation]]></category>
		<category><![CDATA[MI]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77768</guid>
		<description><![CDATA[Abbott Labs (ABT) and partner Reata Pharmaceuticals, Inc. recently announced the presentation of new phase II data on bardoxolone methyl. In addition to being posted online in The New England Journal of Medicine, the data were also presented at the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Congress. The phase II BEAM study was conducted in patients with moderate to severe chronic kidney disease and type II diabetes. Results showed that patients receiving bardoxolone methyl for 52 weeks experienced a sustained improvement in kidney function throughout the treatment period as measured by estimated glomerular filtration rate (eGFR), which is an important measure of kidney function. All three doses (25, 75 or 150 mg) of bardoxolone methyl achieved a statistically significant improvement in eGFR compared to placebo. Moreover, only 9% ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/29/abt-abbott-labs-and-reata-pharmaceuticals-present-new-phase-ii-data/77768/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CMED) China Medical Technologies Collaborates to Grow</title>
		<link>http://www.stockbloghub.com/2011/06/26/cmed-china-medical-technologies-collaborates-to-grow/77425</link>
		<comments>http://www.stockbloghub.com/2011/06/26/cmed-china-medical-technologies-collaborates-to-grow/77425#comments</comments>
		<pubDate>Sun, 26 Jun 2011 17:44:33 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[BEC]]></category>
		<category><![CDATA[Beckman Coulter Inc]]></category>
		<category><![CDATA[China Medical Technologies Inc]]></category>
		<category><![CDATA[CMED]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77425</guid>
		<description><![CDATA[China Medical Technologies, Inc. (CMED), a Chinese in-vitro diagnostic firm, recently revealed that its whole subsidiary – Beijing GP Medical Technologies Co. Ltd. (&#8220;GP Medical&#8221;) has agreed to collaborate with Gaoxin Da An Healthcare Investment Ltd. (&#8220;Da An Health&#8221;) and jointly market and promote molecular diagnostic know-how for clinical diagnostic applications in China. The two partners will work to introduce novel molecular diagnostic products to serve Da An Health&#8217;s hospital clients and leverage Da An Health&#8217;s network of labs for validation of new products. The agreement includes provisions for expanding the scope of the agreement from molecular diagnostic products to the entire product lineup of GP Medical. The Chairman and CEO of China Medical Technologies stated that the collaboration will lead to greater brand recognition and product awareness among a ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/26/cmed-china-medical-technologies-collaborates-to-grow/77425/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABT) Abbott Labs Boosts Immunology Pipeline</title>
		<link>http://www.stockbloghub.com/2011/06/24/abt-abbott-labs-boosts-immunology-pipeline/77422</link>
		<comments>http://www.stockbloghub.com/2011/06/24/abt-abbott-labs-boosts-immunology-pipeline/77422#comments</comments>
		<pubDate>Fri, 24 Jun 2011 22:04:03 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[RA]]></category>
		<category><![CDATA[Railamerica Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77422</guid>
		<description><![CDATA[Abbott Labs (ABT) recently entered into a global agreement with Biotest AG for the development and commercialization of a novel anti-CD4 antibody, BT-061. The Candidate: BT-061 The deal is focused on the development and commercialization of BT-061 for the treatment of rheumatoid arthritis (RA) and psoriasis. BT-061 is currently being evaluated in phase II studies for RA and psoriasis. Moreover, the candidate’s potential to be used for other immune-related diseases is being evaluated in preclinical studies. BT-061 could be differentiated from other anti-CD4 antibodies as it does not cause depletion of CD4 positive T-cells which would lead to weakened immune responses. Terms of the Deal Per the terms of the agreement, BT-061 will be co-promoted by Abbott Labs and Biotest in the five major European markets: Germany, France, United Kingdom, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/24/abt-abbott-labs-boosts-immunology-pipeline/77422/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDT) Medical Devices Stock Outlook &#8211; June 2011 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2011/06/22/mdt-medical-devices-stock-outlook-june-2011-industry-outlook/77179</link>
		<comments>http://www.stockbloghub.com/2011/06/22/mdt-medical-devices-stock-outlook-june-2011-industry-outlook/77179#comments</comments>
		<pubDate>Thu, 23 Jun 2011 01:09:21 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[Abiomed Inc]]></category>
		<category><![CDATA[ABMD]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton Dickinson Company]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[CNMD]]></category>
		<category><![CDATA[Conmed Corporation]]></category>
		<category><![CDATA[Edwards Lifesciences Corporation]]></category>
		<category><![CDATA[EW]]></category>
		<category><![CDATA[Flaherty & Crumrine Preferred Income Opportunity F]]></category>
		<category><![CDATA[HAE]]></category>
		<category><![CDATA[Haemonetics Corporation]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[PFO]]></category>
		<category><![CDATA[S]]></category>
		<category><![CDATA[SMA]]></category>
		<category><![CDATA[Sprint Nextel Corporation]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>
		<category><![CDATA[Stryker Corporation]]></category>
		<category><![CDATA[SYK]]></category>
		<category><![CDATA[Symmetry Medical Inc]]></category>
		<category><![CDATA[Thermo Fisher Scientific Inc]]></category>
		<category><![CDATA[TMO]]></category>
		<category><![CDATA[VAR]]></category>
		<category><![CDATA[Varian Medical Systems Inc]]></category>
		<category><![CDATA[VOLC]]></category>
		<category><![CDATA[Volcano Corporation]]></category>
		<category><![CDATA[WMGI]]></category>
		<category><![CDATA[Wright Medical Group Inc]]></category>
		<category><![CDATA[Zimmer Holdings Inc]]></category>
		<category><![CDATA[ZMH]]></category>
		<category><![CDATA[ZOLL]]></category>
		<category><![CDATA[Zoll Medical Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77179</guid>
		<description><![CDATA[A host of macro headwinds (including price and procedure volume pressure) which hit the MedTech industry last year continued to haunt the sector during the March quarter and encumber growth. Although a number of these issues are expected to linger through the remainder of 2011, the industry is expected to fare relatively better this year thanks to several tailwinds and growth opportunities. Industry Dynamics The global medical devices industry is fairly large, intensely competitive and highly innovative, with estimated worldwide sales of more than $300 billion in 2011. The U.S. is the largest market, with estimated sales of roughly $95 billion in 2010. The medical devices industry is divided into different segments including Cardiology, Oncology, Neuro, Orthopedic and Aesthetic Devices. The U.S. medical devices industry continues to grow at a ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/22/mdt-medical-devices-stock-outlook-june-2011-industry-outlook/77179/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(USA) Company News for June 20, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/06/20/usa-company-news-for-june-20-2011-corporate-summary/76796</link>
		<comments>http://www.stockbloghub.com/2011/06/20/usa-company-news-for-june-20-2011-corporate-summary/76796#comments</comments>
		<pubDate>Mon, 20 Jun 2011 15:23:08 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Closed-End Fund - Equity]]></category>
		<category><![CDATA[Financial]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[BPZ]]></category>
		<category><![CDATA[BPZ Resources Inc]]></category>
		<category><![CDATA[C]]></category>
		<category><![CDATA[Celestica Inc.]]></category>
		<category><![CDATA[CIEN]]></category>
		<category><![CDATA[Ciena Corporation]]></category>
		<category><![CDATA[Citigroup Inc.]]></category>
		<category><![CDATA[CLS]]></category>
		<category><![CDATA[InterMune Inc]]></category>
		<category><![CDATA[ITMN]]></category>
		<category><![CDATA[JPM]]></category>
		<category><![CDATA[JPMorgan Chase & Company]]></category>
		<category><![CDATA[Liberty All Star Equity Fund]]></category>
		<category><![CDATA[Research In Motion Limited]]></category>
		<category><![CDATA[RIMM]]></category>
		<category><![CDATA[Rockwell Automation Inc.]]></category>
		<category><![CDATA[ROK]]></category>
		<category><![CDATA[UBS]]></category>
		<category><![CDATA[UBS AG]]></category>
		<category><![CDATA[USA]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=76796</guid>
		<description><![CDATA[•    Research In Motion Limited (NASDAQ:RIMM) reported first quarter earnings per share of $1.33. While this is marginally higher than the Zacks Consensus EPS Estimate of $1.32 per share, revenue numbers  missed expectations of $5.4 billion by roughly half a billion dollars, coming in at $4.9 billion •    KV Pharmaceutical Co. (NYSE:KV-A) announced plans to sell its generics subsidiary, Nesher Pharmaceuticals Inc, as well as the company&#8217;s generic business and assets to Zydus Pharmaceuticals (USA), Inc. for nearly $60 million in cash. The transaction is likely to close in Q2FY12 •    BPZ Resources, Inc. (NYSE:BPZ) initiated the process to identify and select a partner for its offshore Block Z-1 in northwest Peru •    William Blair initiated coverage on Rockwell Automation Inc. (NYSE:ROK) with a “Market Perform” rating •    Citigroup, Inc. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/20/usa-company-news-for-june-20-2011-corporate-summary/76796/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABT) Abbott Labs&#8217; Bardoxolone in Phase III Trials</title>
		<link>http://www.stockbloghub.com/2011/06/19/abt-abbott-labs-bardoxolone-in-phase-iii-trials/76721</link>
		<comments>http://www.stockbloghub.com/2011/06/19/abt-abbott-labs-bardoxolone-in-phase-iii-trials/76721#comments</comments>
		<pubDate>Sun, 19 Jun 2011 17:25:12 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Marshall & Ilsley Corporation]]></category>
		<category><![CDATA[MI]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=76721</guid>
		<description><![CDATA[Abbott Labs (ABT) and partner Reata Pharmaceuticals, Inc. recently commenced a pivotal phase III study with bardoxolone methyl. Bardoxolone methyl’s safety and efficacy will be evaluated in patients with chronic kidney disease and type II diabetes. Study Design The multinational, double-blind, placebo-controlled phase III study, BEACON (Bardoxolone methyl EvAluation in patients with Chronic kidney disease and type 2 diabetes: the Occurrence of renal eveNts), will be conducted with about 1,600 patients across 300 sites. Patients will be randomized 1:1 to receive either a 20 mg reformulated version of bardoxolone methyl or placebo once daily. While the primary efficacy endpoint is a time-to-first-event composite consisting of progression to end-stage renal disease (ESRD) and cardiovascular death, secondary endpoints include change in estimated glomerular filtration rate (eGFR) and a time-to-first-event composite consisting of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/19/abt-abbott-labs-bardoxolone-in-phase-iii-trials/76721/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(JNJ) Johnson &amp; Johnson to Discontinue Cypher Stent</title>
		<link>http://www.stockbloghub.com/2011/06/16/jnj-johnson-johnson-to-discontinue-cypher-stent/76575</link>
		<comments>http://www.stockbloghub.com/2011/06/16/jnj-johnson-johnson-to-discontinue-cypher-stent/76575#comments</comments>
		<pubDate>Thu, 16 Jun 2011 21:59:41 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[DES]]></category>
		<category><![CDATA[El Paso Corporation]]></category>
		<category><![CDATA[EP]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[WisdomTree SmallCap Dividend]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=76575</guid>
		<description><![CDATA[Cordis Corporation, a Johnson &#38; Johnson (JNJ) company, recently announced that it will stop manufacturing Cypher and Cypher Select Plus sirolimus-eluting coronary stents by year end. The company will also discontinue the development of Nevo sirolimus-eluting coronary stent. Cordis intends to focus on other cardiovascular therapies instead. Cypher Sales Were Under Pressure The decision to discontinue Cypher stent does not come as a surprise given the declining sales of the product. Changing dynamics in the drug-eluting stent (DES) market along with unlicensed competition from products infringing Cordis’ patents led to an erosion in Cypher stent’s pricing, sales and market share. Moreover, the launch of superior products by competitors also led to a loss of market share. On the first quarter call, Johnson &#38; Johnson reported a 41% decline in Cypher ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/16/jnj-johnson-johnson-to-discontinue-cypher-stent/76575/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(JNJ) Pharma &amp; Biotech Stock Outlook &#8211; June 2011 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2011/06/14/jnj-pharma-biotech-stock-outlook-june-2011-industry-outlook/76371</link>
		<comments>http://www.stockbloghub.com/2011/06/14/jnj-pharma-biotech-stock-outlook-june-2011-industry-outlook/76371#comments</comments>
		<pubDate>Wed, 15 Jun 2011 03:24:14 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[AGN]]></category>
		<category><![CDATA[Allergan Inc.]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Perrigo Company]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PRGO]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=76371</guid>
		<description><![CDATA[Challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition, pipeline failures and limited late-stage catalysts continue to impact the pharmaceutical industry. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. All these factors will lead to a slowdown in global pharmaceutical market growth in the next five years. Products like Lipitor, Plavix, Lexapro and Zyprexa are expected to face generic competition over the next five years. In fact, 2011 itself will see drugs worth more than $30 billion losing patent protection. This includes drugs like Lipitor, Zyprexa and Levaquin. The effect of the genericization of these products will be felt mostly in 2012, which will be a challenging year for several companies. At the same time, new products are ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/14/jnj-pharma-biotech-stock-outlook-june-2011-industry-outlook/76371/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYL) Mylan Launches New Generic Pharmaceuticals</title>
		<link>http://www.stockbloghub.com/2011/05/27/myl-mylan-launches-new-generic-pharmaceuticals/75053</link>
		<comments>http://www.stockbloghub.com/2011/05/27/myl-mylan-launches-new-generic-pharmaceuticals/75053#comments</comments>
		<pubDate>Fri, 27 May 2011 13:40:29 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[ISTA]]></category>
		<category><![CDATA[ISTA Pharmaceuticals Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Par Pharmaceutical Companies Inc]]></category>
		<category><![CDATA[PRX]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=75053</guid>
		<description><![CDATA[Mylan Inc.’s (MYL) generic portfolio continued to be boosted with the launch of the generic version of Xanodyne Pharmaceutical’s pain reliever Roxicodone. The generic has been launched under a development and supply agreement with Coastal Pharmaceuticals. The product recorded sales of $325 million in US for the twelve months endied March 31, 2011 according to data released by IMS Health. We note that the launch of the generic version of the pain reliever is the latest in the series of generic launches at Mylan. A couple of days ago the company, which is one of the largest generic and specialty pharmaceutical companies across the globe, launched its generic version of Abbott Laboratories’ (ABT) Depakote Sprinkle Capsules for treating seizures. The product recorded sales of $89 million in US for the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/27/myl-mylan-launches-new-generic-pharmaceuticals/75053/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VIVO) FDA OKs Meridian C. Difficile Test</title>
		<link>http://www.stockbloghub.com/2011/05/13/vivo-fda-oks-meridian-c-difficile-test/74020</link>
		<comments>http://www.stockbloghub.com/2011/05/13/vivo-fda-oks-meridian-c-difficile-test/74020#comments</comments>
		<pubDate>Fri, 13 May 2011 20:25:43 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton Dickinson Company]]></category>
		<category><![CDATA[Meridian Bioscience Inc.]]></category>
		<category><![CDATA[SI]]></category>
		<category><![CDATA[Siemens AG]]></category>
		<category><![CDATA[Thermo Fisher Scientific Inc]]></category>
		<category><![CDATA[TMO]]></category>
		<category><![CDATA[VIVO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=74020</guid>
		<description><![CDATA[Diagnostic test kit maker Meridian Bioscience (VIVO) has clinched the approval of U.S. Food and Drug Administration (“FDA”) for its new C. difficile (Clostridium difficile) test dubbed Premier C. difficile GDH. The approval of this next-generation test broadens the Cincinnati-based company’s portfolio of C. difficile tests and underscores its sustained commitment to bring out breakthrough products for the detection of C. difficile. Premier GDH has been marketed in Europe since October 2010. C. difficile is a highly drug-resistant bacterium which exists in the environment in spore (or inactive) form and produces a toxin that causes diarrhea and more serious intestinal conditions such as colitis. C. difficile spores are frequently found in hospitals, nursing homes and extended care facilities. Although spores cannot cause infection directly, they transform into the active (or ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/13/vivo-fda-oks-meridian-c-difficile-test/74020/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABT) Abbott Laboratories Earns FDA Approval of AndroGel</title>
		<link>http://www.stockbloghub.com/2011/05/05/abt-abbott-laboratories-earns-fda-approval-of-androgel/73465</link>
		<comments>http://www.stockbloghub.com/2011/05/05/abt-abbott-laboratories-earns-fda-approval-of-androgel/73465#comments</comments>
		<pubDate>Fri, 06 May 2011 01:36:49 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Auxilium Pharmaceuticals Inc.]]></category>
		<category><![CDATA[AUXL]]></category>
		<category><![CDATA[BioSante Pharmaceuticals Inc]]></category>
		<category><![CDATA[BPAX]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Endo Pharmaceuticals Holdings Inc]]></category>
		<category><![CDATA[ENDP]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Repros Therapeutics Inc]]></category>
		<category><![CDATA[RPRX]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=73465</guid>
		<description><![CDATA[Abbott Laboratories (ABT) recently gained US Food and Drug Administration (FDA) approval for AndroGel (testosterone gel) 1.62%. The gel formulation is approved for the treatment of hypogonadism (low or zero testosterone levels) in adult men. Abbott Labs already has a product in its portfolio for this indication – AndroGel 1%. However, Abbott Labs said that AndroGel 1.62% has the ability to restore testosterone levels in hypogonadal men with half the volume of gel at the starting dose compared to AndroGel 1%. Results from a study showed that 82% of patients taking AndroGel 1.62% achieved a normal average testosterone level on day 112. AndroGel 1.62% will be available from the second quarter of 2011. AndroGel 1.62% became a part of Abbott Labs’ portfolio with its Feb 2010 acquisition of Solvay Pharmaceuticals. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/05/abt-abbott-laboratories-earns-fda-approval-of-androgel/73465/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(DXCM) DexCom Misses Analyst Estimates</title>
		<link>http://www.stockbloghub.com/2011/05/05/dxcm-dexcom-misses-analyst-estimates/73288</link>
		<comments>http://www.stockbloghub.com/2011/05/05/dxcm-dexcom-misses-analyst-estimates/73288#comments</comments>
		<pubDate>Thu, 05 May 2011 15:47:43 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[DexCom Inc]]></category>
		<category><![CDATA[DXCM]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=73288</guid>
		<description><![CDATA[DexCom (DXCM), a prominent player in the glucose monitoring market, reported first-quarter fiscal 2011 loss per share of 19 cents, a penny higher than  the Zacks Consensus Estimate while sharply less than the year-ago loss of 40 cents per share. Net loss for the quarter trimmed roughly 41.5% year over year to $11.9 million owing to a healthy revenue growth. Revenues Revenues for the quarter shot up roughly 48.5% year over year to $14.2 million, still missing the Zacks Consensus Estimate of $15 million. Product sales almost doubled year over year to $13.1 million while development grant and other revenues dropped 62.8% to slightly over $1 million. Margins and Expenses Gross margin for the quarter dipped slightly to 36.1% from 36.2% a year ago. Operating expenses leaped 16.9% year over ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/05/dxcm-dexcom-misses-analyst-estimates/73288/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HOLX) Hologic Earnings Report Shows Strong Growth</title>
		<link>http://www.stockbloghub.com/2011/05/04/holx-hologic-earnings-report-shows-strong-growth/73177</link>
		<comments>http://www.stockbloghub.com/2011/05/04/holx-hologic-earnings-report-shows-strong-growth/73177#comments</comments>
		<pubDate>Wed, 04 May 2011 16:37:36 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Conceptus Inc]]></category>
		<category><![CDATA[CPTS]]></category>
		<category><![CDATA[Hologic Inc]]></category>
		<category><![CDATA[HOLX]]></category>
		<category><![CDATA[QGEN]]></category>
		<category><![CDATA[Qiagen NV]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=73177</guid>
		<description><![CDATA[Hologic (HOLX) reported an adjusted EPS of 30 cents during the second quarter of fiscal 2011, surpassing the Zacks Consensus Estimate by 2 cents and a penny above the year-ago quarter. Revenues were $438.7 million, an increase of 4.9% compared to the prior-year quarter and higher than the Zacks Consensus Estimate of $433 million. Hologic operates through four segments ? Breast Health, Diagnostics, GYN (Gynecology) Surgical and Skeletal Health ? which contributed 47%, 32%, 16% and 5%, respectively to the total revenue during the quarter. Barring Diagnostics revenue, which declined 1.2% to $138.2 million during the quarter, the other three segments recorded a robust growth of 8.7% ($205.9 million), 6.5% ($71.5 million) and 7.1% ($23.1 million), respectively. The strong growth witnessed by Breast Health was primarily driven by the rise ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/04/holx-hologic-earnings-report-shows-strong-growth/73177/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMGN) Amgen Beats First Quarter Estimates &#8211; Maintains Outlook</title>
		<link>http://www.stockbloghub.com/2011/04/27/amgn-amgen-beats-first-quarter-estimates-maintains-outlook/72064</link>
		<comments>http://www.stockbloghub.com/2011/04/27/amgn-amgen-beats-first-quarter-estimates-maintains-outlook/72064#comments</comments>
		<pubDate>Wed, 27 Apr 2011 17:52:52 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=72064</guid>
		<description><![CDATA[Amgen (AMGN) reported first quarter earnings per share of $1.32, 3 cents above the Zacks Consensus Estimate of $1.29 and 3.1% above year-ago earnings. Higher revenues, a lower tax rate and lower share count helped drive first quarter results. Including one-time items, earnings increased 2% to $1.20 in the first quarter of 2011. Total revenues increased 3.2% to $3,706 million in the first quarter of 2011. Revenues topped the Zacks Consensus Estimate of $3,662 million. US revenues increased 4% during the quarter to $2,778 million. Meanwhile, international revenues dropped 1% to $840 million. Foreign exchange (Fx) fluctuation negatively impacted revenues during the first quarter. While Xgeva was off to a strong start, Epogen performance disappointed. The Quarter in Detail First quarter total product sales increased 2.6% to $3,618 million. Revenues ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/27/amgn-amgen-beats-first-quarter-estimates-maintains-outlook/72064/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(INTC) Staying Power of the Earnings Growth Momentum</title>
		<link>http://www.stockbloghub.com/2011/04/20/intc-staying-power-of-the-earnings-growth-momentum/71967</link>
		<comments>http://www.stockbloghub.com/2011/04/20/intc-staying-power-of-the-earnings-growth-momentum/71967#comments</comments>
		<pubDate>Wed, 20 Apr 2011 21:37:39 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Semiconductor - Broad Line]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[AAPL]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Apple Inc.]]></category>
		<category><![CDATA[AT&T Inc.]]></category>
		<category><![CDATA[CSX]]></category>
		<category><![CDATA[CSX Corporation]]></category>
		<category><![CDATA[Eaton Corporation]]></category>
		<category><![CDATA[ETN]]></category>
		<category><![CDATA[IBM]]></category>
		<category><![CDATA[INTC]]></category>
		<category><![CDATA[Intel Corporation]]></category>
		<category><![CDATA[International Business Machines]]></category>
		<category><![CDATA[T]]></category>
		<category><![CDATA[United Technologies Corporation]]></category>
		<category><![CDATA[UTX]]></category>
		<category><![CDATA[Verizon Communications Inc.]]></category>
		<category><![CDATA[VZ]]></category>
		<category><![CDATA[Wells Fargo & Company]]></category>
		<category><![CDATA[WFC]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=71967</guid>
		<description><![CDATA[Wednesday, April 20, 2011 With the earnings season getting into full gear, I am increasingly getting more optimistic about the staying power of the earnings growth momentum. My favorable takeaway does not reflect the stand-out results from tech bellwethers like Intel (INTC) and IBM (IBM) only. There is broad-based strength, from railroads to diversified industrials, which should reassure the market of the sustainability of the economic recovery. i will be looking for stocks to start reflecting this favorable trend. Intel and IBM may no longer be in the vanguard of the technology revolution, but they do provide an excellent early look into global technology spending patterns. Intel&#8217;s comments about low double-digit growth in global PC market is particularly important, as it runs counter to the consensus view of &#8216;flattish&#8217; growth ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/20/intc-staying-power-of-the-earnings-growth-momentum/71967/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABT) Abbott Labs First Quarter 2011 Earnings Preview</title>
		<link>http://www.stockbloghub.com/2011/04/18/abt-abbott-labs-first-quarter-2011-earnings-preview/71667</link>
		<comments>http://www.stockbloghub.com/2011/04/18/abt-abbott-labs-first-quarter-2011-earnings-preview/71667#comments</comments>
		<pubDate>Mon, 18 Apr 2011 14:31:41 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=71667</guid>
		<description><![CDATA[Abbott Laboratories (ABT) is all set to announce its first quarter 2011 results on April 20, 2011 before the opening bell. The Zacks Consensus Estimate for the first quarter of 2011 is $0.90, representing a year-over-year increase of 11.1%. Abbott Labs has surpassed earnings estimates consistently in the last four quarters with a trailing four-quarter average of 1.0%. Fourth Quarter 2010 Recap Abbott Laboratories reported fourth quarter earnings of $1.30 per share, a penny above the Zacks Consensus Estimate. Earnings increased 10.2% from the year-ago period. Higher revenues helped drive results. However, including one-time items, earnings declined 6.1% to $0.92 per share. Fourth quarter revenues increased 13.4% to $9.97 billion, above the Zacks Consensus Estimate of $9.89 billion. (Read our full coverage on the earnings report at Abbott Labs Tops ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/18/abt-abbott-labs-first-quarter-2011-earnings-preview/71667/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYGN) Myriad Genetics and BioMarin Pharmaceuticals Enter Agreement for Testing</title>
		<link>http://www.stockbloghub.com/2011/04/09/mygn-myriad-genetics-and-biomarin-pharmaceuticals-enter-agreement-for-testing/70983</link>
		<comments>http://www.stockbloghub.com/2011/04/09/mygn-myriad-genetics-and-biomarin-pharmaceuticals-enter-agreement-for-testing/70983#comments</comments>
		<pubDate>Sat, 09 Apr 2011 19:13:47 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Biomarin Pharmaceutical Inc]]></category>
		<category><![CDATA[BMRN]]></category>
		<category><![CDATA[MYGN]]></category>
		<category><![CDATA[Myriad Genetics Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=70983</guid>
		<description><![CDATA[Myriad Genetics (MYGN) has entered into an agreement with BioMarin Pharmaceuticals (BMRN) to conduct BRCA1 and BRCA2 mutation testing on patients to be enrolled in the latter’s phase I/II clinical study of BMN 673. BMN 673 is a PARP-inhibitor drug candidate for treatment of genetically defined cancers. Bracanalysisis Myriad’s flagship product, contributing 89% of total revenue. This test provides a comprehensive analysis of BRCA1 and BRCA2 genes for assessing woman&#8217;s risk of hereditary breast and ovarian cancers. Under the agreement, the company will carry out Bracanalysis test to identify the presence of germline mutations in the patients prior to enrollment in the study. Accordingly, it will provide standard test reports to the clinicians. Myriad is aiming at establishing itself as a strong player in the companion diagnostic market. To establish ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/09/mygn-myriad-genetics-and-biomarin-pharmaceuticals-enter-agreement-for-testing/70983/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BSX) Boston Scientific Presents Positive Stent Results</title>
		<link>http://www.stockbloghub.com/2011/04/07/bsx-boston-scientific-presents-positive-stent-results/70771</link>
		<comments>http://www.stockbloghub.com/2011/04/07/bsx-boston-scientific-presents-positive-stent-results/70771#comments</comments>
		<pubDate>Thu, 07 Apr 2011 15:19:12 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=70771</guid>
		<description><![CDATA[Boston Scientific (BSX) presented an analysis on data derived from two trials – Perseus and Taxus Atlas at the American College of Cardiology annual conference. It was observed that the Ion platinum chromium (PtCr) paclitaxel-eluting stent system (Taxus Element) compared favorably to the currently available Taxus Liberte paclitaxel-eluting stent system. Both the stents employ the same drug and polymer. However, the former demonstrated better performance in case of major adverse cardiac events and myocardial infarcation among the patients. Data from about 2,298 patients enrolled in the Perseus and Taxus Atlas trials were analyzed. While the Taxus Element stent system is available in Europe (received CE Mark approval in May 2010), it is yet to be approved in the US. Boston Scientific expects to launch the Taxus Element stent system as ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/07/bsx-boston-scientific-presents-positive-stent-results/70771/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(LLY) Eli Lilly&#8217;s Axiron Testosterone Deficiency Drug Launched in the U.S.</title>
		<link>http://www.stockbloghub.com/2011/04/05/lly-eli-lillys-axiron-testosterone-deficiency-drug-launched-in-the-u-s/70638</link>
		<comments>http://www.stockbloghub.com/2011/04/05/lly-eli-lillys-axiron-testosterone-deficiency-drug-launched-in-the-u-s/70638#comments</comments>
		<pubDate>Tue, 05 Apr 2011 15:52:15 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Auxilium Pharmaceuticals Inc.]]></category>
		<category><![CDATA[AUXL]]></category>
		<category><![CDATA[BioSante Pharmaceuticals Inc]]></category>
		<category><![CDATA[BPAX]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Endo Pharmaceuticals Holdings Inc]]></category>
		<category><![CDATA[ENDP]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Repros Therapeutics Inc]]></category>
		<category><![CDATA[RPRX]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=70638</guid>
		<description><![CDATA[Eli Lilly and Company (LLY) recently announced the availability of Axiron in pharmacies across the US. Axiron gained approval from the US Food and Drug Administration (FDA) in November 2010 for use as a replacement therapy in men for certain conditions associated with testosterone deficiency or absence. Axiron Rights Acquired in March 2010 Eli Lilly acquired exclusive worldwide rights from Australian company, Acrux, to commercialize Axiron in March 2010. Per the terms of the deal, Eli Lilly made an upfront payment of $50 million and $3 million on the transfer of manufacturing assets. The FDA approval of Axiron triggered a milestone payment of $87 million from Eli Lilly. Acrux could receive up to $195 million in commercialization milestones, and royalty payments on global sales of the product. Men’s Health Portfolio ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/05/lly-eli-lillys-axiron-testosterone-deficiency-drug-launched-in-the-u-s/70638/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDT) Medical Devices Industry Outlook &#8211; April 2011 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2011/03/31/mdt-medical-devices-industry-outlook-april-2011-industry-outlook/70413</link>
		<comments>http://www.stockbloghub.com/2011/03/31/mdt-medical-devices-industry-outlook-april-2011-industry-outlook/70413#comments</comments>
		<pubDate>Thu, 31 Mar 2011 23:07:44 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[Abiomed Inc]]></category>
		<category><![CDATA[ABMD]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Accuray Incorporated]]></category>
		<category><![CDATA[Allscripts-Misys Healthcare Solutions Inc]]></category>
		<category><![CDATA[ARAY]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton Dickinson Company]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[CNMD]]></category>
		<category><![CDATA[Conmed Corporation]]></category>
		<category><![CDATA[Cyberonics Inc]]></category>
		<category><![CDATA[CYBX]]></category>
		<category><![CDATA[Flaherty & Crumrine Preferred Income Opportunity F]]></category>
		<category><![CDATA[HAE]]></category>
		<category><![CDATA[Haemonetics Corporation]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MDRX]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[PFO]]></category>
		<category><![CDATA[QSII]]></category>
		<category><![CDATA[Quality Systems Inc.]]></category>
		<category><![CDATA[SMA]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>
		<category><![CDATA[Stryker Corporation]]></category>
		<category><![CDATA[SYK]]></category>
		<category><![CDATA[Symmetry Medical Inc]]></category>
		<category><![CDATA[TOMO]]></category>
		<category><![CDATA[TomoTherapy Incorporated]]></category>
		<category><![CDATA[VAR]]></category>
		<category><![CDATA[Varian Medical Systems Inc]]></category>
		<category><![CDATA[VOLC]]></category>
		<category><![CDATA[Volcano Corporation]]></category>
		<category><![CDATA[WMGI]]></category>
		<category><![CDATA[Wright Medical Group Inc]]></category>
		<category><![CDATA[Zimmer Holdings Inc]]></category>
		<category><![CDATA[ZMH]]></category>
		<category><![CDATA[ZOLL]]></category>
		<category><![CDATA[Zoll Medical Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=70413</guid>
		<description><![CDATA[Last year was challenging for medical device companies given the exigent economic conditions and an uncertain healthcare environment. The MedTech industry was hit by several macro headwinds in 2010 including price/volume and utilization pressure and a more restrictive regulatory environment. Although a number of these issues remain, the industry is expected to fare better this year due to several tailwinds and growth opportunities. Industry Dynamics The global medical devices industry is fairly large, intensely competitive and highly innovative, with estimated worldwide sales of more than $300 billion in 2011. The U.S. is the largest medical devices market, with estimated sales of roughly $95 billion in 2010. The medical devices industry is divided into different segments such as Cardiology, Oncology, Neuro, Orthopedic, Aesthetic Devices and Healthcare IT (“HCIT”). The U.S. medical ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/03/31/mdt-medical-devices-industry-outlook-april-2011-industry-outlook/70413/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(JNJ) Japan Quake Impact on Medical Technology</title>
		<link>http://www.stockbloghub.com/2011/03/28/jnj-japan-quake-impact-on-medical-technology/68708</link>
		<comments>http://www.stockbloghub.com/2011/03/28/jnj-japan-quake-impact-on-medical-technology/68708#comments</comments>
		<pubDate>Tue, 29 Mar 2011 02:41:55 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[COV]]></category>
		<category><![CDATA[Covidien plc]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>
		<category><![CDATA[Stryker Corporation]]></category>
		<category><![CDATA[SYK]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=68708</guid>
		<description><![CDATA[Tremors triggering a quake, which struck about 250 miles north of Tokyo, followed by a colossal Tsunami, wreaked havoc on the people of the “Land of the Rising Sun” on March 11, resulting in massive carnage and destruction. The catastrophe, which is believed to have already claimed at least 10,000 lives (mostly in the northern port of Sendai) with tens of thousands still missing, has entered  the book as the largest ever in the island nation’s recorded history. Japan in Dire Straits While the human casualty is enormous, the calamity has struck a major blow to the nation’s ailing economy. The Japanese economy is forecast to slow down in 2011 (projected GDP growth of 1.3% versus 3.9% in 2010) as political instability continues to weigh on the country’s economic prospects. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/03/28/jnj-japan-quake-impact-on-medical-technology/68708/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(JNJ) Pharmaceutical Industry Outlook &#8211; March 2011 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2011/03/02/jnj-pharmaceutical-industry-outlook-march-2011-industry-outlook/67917</link>
		<comments>http://www.stockbloghub.com/2011/03/02/jnj-pharmaceutical-industry-outlook-march-2011-industry-outlook/67917#comments</comments>
		<pubDate>Thu, 03 Mar 2011 01:14:57 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[AGN]]></category>
		<category><![CDATA[Allergan Inc.]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MannKind Corporation]]></category>
		<category><![CDATA[MNKD]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=67917</guid>
		<description><![CDATA[The pharmaceutical industry continues to witness major challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition, pipeline failures and limited late-stage catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. According to IMS Health, this is the main reason global pharmaceutical market growth will be restricted to the mid-single digits (5-8%) through 2014. Over the next five years, products that currently generate more than $142 billion in sales are expected to face generic competition, including Lipitor, Plavix and Zyprexa. In fact, 2011 itself will see products worth more than $30 billion losing patent protection. This includes products like Lipitor, Plavix, Zyprexa and Levaquin. These products generated more than $15 billion in sales in 2010. The effect of the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/03/02/jnj-pharmaceutical-industry-outlook-march-2011-industry-outlook/67917/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

